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Abstract 
Background — Acute pancreatitis is an inflammatory disease, which arises from the 
premature activation of acinar digestive zymogens in the pancreas, thus causing an 
autodigestion of the gland. The pathogenesis of acute pancreatitis is thought to be 
multi-factorial. Apart from the activation of proteolytic enzymes, the activation of 
kinins and vasoactive peptides such as angiotensin II (Ang II) would also be involved. 
The renin-angiotensin system (RAS) in the pancreas has been shown to be 
dramatically up-regulated by an experimental model of cerulein-induced acute 
pancreatitis. Angiotensin converting enzyme (ACE) inhibitor has been demonstrated 
to provide defensive effects against pancreatic inflammation and fibrosis. The 
present study hypothesized that inhibition of the pancreatic RAS by specific RAS 
inhibitors could have a role for changes in the severity of pancreatic injury and 
oxidative stress induced by acute pancreatitis. In addition, the present study also 
investigated the existence of RAS in the exocrine pancreas, and its involvement in 
regulating the acinar digestive enzyme secretion and in acute pancreatitis. 
Methodology — A rat model of cerulein-induced acute pancreatitis was utilized in 
assessing the inhibition of the RAS on the changes in the severity of tissue injury and 
oxidative stress in the pancreas. Biochemical and histopathological approaches were 
exploited to evaluate the differential effects of RAS inhibitions. Furthermore, the 
existence of RAS components and their regulation in isolated pancreatic acini were 
examined by means of reverse transcription-polymerase chain reaction analysis. On 
the other hand, the potential role of Ang II in acinar digestive secretion coupled with 
specific antagonists for Ang II receptors was explored. 
Results — Indicators for pancreatic injury, such as tissue edema, plasma 
hyperamylasemia and hyperlipasemia, were significantly reduced in acute 
i 
pancreatitis-induced pancreas when the specific ATi receptor antagonist, losartan 
and the non-specific Ang II receptor antagonist, saralasin were applied. Suppression 
in oxidative stress was also observed as indicated by a marked decrease in 
glutathione depletion, protein and lipid oxidative modifications. However, the ACE 
inhibitor, ramiprilat and the specific AT2 receptor antagonist, PD123319 did not 
provide any suppressive properties against the acute pancreatitis-induced injury and 
oxidative stress. Histopathological evaluations were in close agreement with those 
results from biochemical assays. On the other hand, exogenous Ang II was found to 
stimulate a concentration-dependent release of a-amylase in isolated pancreatic acini. 
Upon the application of ATi receptor antagonist, the Ang Il-evoked a-amylase 
secretion was significantly inhibitable from acinar cells; however, the AT2 receptor 
antagonist did not exhibit such an effect. In those acute pancreatitis-induced 
pancreatic acini, the a-amylase secretion was subjected to a marked increase, which 
was again inhibitable by the ATi receptor antagonist. On the other hand, preliminary 
data showed that ATi receptor antagonist also provided defensive effects against 
acute pancreatitis-induced systemic inflammation. 
Conclusion — The experimental results suggest that the pancreatic RAS may play an 
important role in the regulation of exocrine acinar functions such as digestive 
enzyme secretion. The activation of such a pancreatic RAS by acute pancreatitis 
may exert critical influences in the severity of tissue injury and oxidative stress. To 
this end, the differential effects of RAS inhibitors on the changes in pancreatic injury 
could provide an alternative strategy for the potential treatment for acute pancreatitis; 
otherwise acute pancreatitis may lead to serious complications such as systemic 
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Chapter 1 Introduction 
1.1 Renin-angiotensin system (RAS) 
Historically, the story and study of RAS had begun when two Swedish physiologists 
Robert Tigerstedt and Per Bergmann [1896] at the Karolinska Institute proposed their 
observation of a kidney-derived hormone [Lavoie and Sigmund 2003]. They named 
the discovered hormone renin, which could produce an acute elevation of blood 
pressure. Their discovery of the vasopressor property of renin was first published in 
the Scandinavian Archives of Physiology [1898]. In the second place, the production 
of experimental renal hypertension by Harry Goldbatt [1940] implicated the linkage 
between the kidney-derived vasopressor hormone and the decrease in blood supply. 
Through a lot of research studies, the interaction between renin and blood pressure 
was eventually revealed until the circulating endocrine system RAS had been 
delineated by the pioneering research of Irvine Page [1958]. Renin and angiotensin 
converting enzyme (ACE) are the two main enzymatic characters of the complex 
hormonal system RAS. The macroglobulin angiotensinogen is the precursor for the 
generation of RAS products including angiotensin I (Ang I), angiotensin II (Ang II), 
angiotensin 1-7, angiotensin III (Ang III) and angiotensin IV (Ang IV) [Semple et al. 
1976; Ferrario et al. 1991; Swanson et al 1992]. Physiological actions of the RAS 
are carried out when the angiotensins bind to their cognate receptors ATia, ATib, AT2, 
AT3, AT4 and AT7 [de Gasparo et al 2000]. The RAS has been studied extensively 
over the past three decades for its systemic functions as a circulating RAS. 
Contemporary research studies have put great interest and emphasis on the specific 
activities of intrinsic RAS in local tissues. Up to now, the importance of RAS is still 
a hotbed of research. 
I 
1.1.1 Circulating RAS 
The integral RAS plays an important homeostatic role in regulating blood volume, 
arterial pressure, aldosterone secretion, sodium and fluid balance in the circulation 
[Peach 1977; Ferrario 1990]. The circulating RAS cascade (Fig. 1-1 A), which has 
been well documented, starts from the cleavage of angiotensinogen into a 
decapeptide Ang I by the aspartyl protease renin. Angiotensinogen is originated 
from the liver and is abundant in blood. Its synthesis is stimulated by a number of 
hormones such as glucocorticoids, thyroid hormone as well as Ang II [Menard 1983; 
Vallotton 1987]. Renin is released from the juxtaglomerular cells of kidney into the 
bloodstream in response to hypovolaemia and hypotension. Neurogenic and 
hormonal signals also participate in the regulation of renin secretion [Hackenthal et 
al. 1990]. The ACE from the pulmonary vasculature immediately converts the 
biological inactive product Ang I into an active octapeptide Ang II, which is the 
principal effector peptide of the RAS [Menard et al. 1993]. Ang II targets, at least, at 
two of its cognate receptor subtypes, designated ATi and AT2. It exhibits its 
biological effects at various levels to increase the vascular resistance and blood 
pressure in order to restore homeostasis of the circulation [Unger et al. 1996]. 
Therefore, Ang II is believed to be the principal vasoactive hormone of the RAS 
responsible for vasoconstriction, aldosterone release as well as trophic effects. It is 
generally accepted that the G-protein coupled ATi receptor mediates most of the 
well-established physiological and pathophysiological actions of Ang II 
[Timmermans et al 1993]. However, the role of AT2 receptor is still largely 
unknown; it may play a counter-balancing role to the ATi receptor [Hein et al. 1995]. 
On the other hand, Ang II could be further converted into a number of 
bioactive metabolites such as Ang III and Ang IV by various aminopeptidases. 
2 
Another angiotensin metabolite, Ang 1 -7 could also be generated upon the action of 
prolyl-endopeptidase that exerts a cleavage of Pro-Phe bond from Ang I [Corvol et al 
1995] (Fig. 1-1 A). In addition to the dominant role of Ang II, emerging evidence has 
shown that Ang III, Ang IV and Ang 1 -7 also exhibit physiological RAS functions 
via their respective receptors (Fig. 1-lB) [Ardaillou and Chansel 1997]. In fact, Ang 
1-7 has been shown to act as a vasodilator as well as a cell-growth inhibitor [Ferrario 
and Iyer 1998]. It is also reported to perform biological effects opposite to Ang II, 
such as stimulating phosphatase activities and nitric oxide production through the 
mediation of AT7 receptor [Leung and Chappell 2003]. Ang II acts on the ATi and 
ATi receptors; however, the AT3 receptor for Ang III has been characterized to be 
different from the ATi and AT2 receptors since neither AT 1-specific nor AT2-specific 
agents could block its binding to Ang II [Chaki and Inagami 1992]. Ang III is 
suggested to be involved in the production of chemokine and the regulation of cell 
growth [Ruiz-Ortega et al. 2000]; it may also be involved in the evolution of renal 
damage [Ruiz-Ortega et al. 2001]. The AT4 receptor was identified and appeared to 
be responsible for the dilatation of arterioles in the brain [Haberl et al 1991]. Ang 
IV seems to increase cell proliferation [Pawlikowski and Kunert-Radek 1997] and 
may take part in proinflammatory processes [Ruiz-Ortega et al 2001] through the 
mediation of AT4 receptor. 
The RAS has been suggested to regulate the production of reactive oxygen 
species and reactive nitrogen species in the circulation [Fernandez-Alfonso and 
Gonzalez 1999]. The imbalance production of Ang II and reactive oxygen/nitrogen 
species would probably lead to endothelial dysfunction, cardiovascular disease and 
renal injury [de Gasparo et al 2002]. Over the past decades, a number of studies 
3 
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Fig. 1-1 (A) The schematic presentation of the renin-angiotensin system pathway. 
(B) Amino acid sequences of angiotensin peptides and their respective receptors. 
4 
1.1.2 Tissue-specific RAS 
A large body of investigations has ascertained the existence of the so-called tissue-
specific RAS. Such an intrinsic tissue RAS may produce angiotensinogen, renin and 
ACE thus the locally formed Ang II within individual tissue [Campbell 1987a; 
Campbell 1987b]. This tissue-specific RAS is found to have potential roles in 
mediating autocrine/paracrine effects in order to regulate the end-organ functions 
independently of or additionally to the systemic RAS [Ferrario 1990b, Vinson et al. 
1995]. Key components of the intrinsic RAS have been successionally identified in a 
wide range of tissues, including adrenals [Capponi and Catt 1980], brain 
[Mendelsohn et al. 1984], kidney [Okura et al. 1992], pituitary [Trolliet and Phillips 
1992), heart [Phillips et al. 1993], gonads [Vinson et al 1997], pancreas [Leung and 
Chappell 2003] and lung [Cargill and Lipworth 1995]. 
The detection of renin and angiotensinogen mRNA in vascular tissue 
implicated the local generation of Ang T as well as its consequent product Ang II 
[Kato et al 1993; Campbell and Habener 1986]. The presence of RAS in the 
vascular wall of normoreninemic renal hypertensive rats has been demonstrated to 
play a significant role in maintaining the high blood pressure as implicated by the 
hypotensive effect of intravenous administration of EXP 3174, a specific ATi 
receptor antagonist [Basso et al 1995]. Besides, the cerebral RAS could play an 
important role in the regulation of cerebral blood flow (CBF) during hypoxia in 
rabbit as the increase in CBF was attenuated by RAS inhibitions [Mazen et al 1995]. 
Furthermore, the adrenal RAS has been reported to regulate the tissue growth and 
functions of glomerulosa in rat [Vinson 1995]. The cardiac RAS has been shown to 
play a regulatory role in cardiac hypertrophy and remodeling [Dostal 2000] as well 
as in the pathogenesis of atherosclerosis [Schieffer et al 2000]. 
5 
Activation of a local RAS is believed to result from the local elevation of 
ACE activity and the generation of Ang II. An increase in cardiac ACE activity has 
been observed after an experimental model of myocardial infarction [Johnston et al 
1991]. This data suggested that harmful effects might be inducible from the 
activation of tissue cardiac RAS, rather than just the circulating RAS. Therefore, 
ACE inhibitor could probably be able to inhibit tissue RAS in order to manage not 
only hypertension, but also cardiovascular diseases [Barsotti et al. 2001], renal 
diseases [Gansevoort et al 1993] and tissue fibrosis [Border and Noble 2001]. A 
large body of works has substantiated that the locally generated Ang II may carry 
significant proinflammatory actions, such as the production of reactive oxygen 
species, inflammatory cytokines, chemokines, and the modulating abilities in cell 
growth/apoptosis and injury/repair of the end-tissue. In this respect, the liver-derived 
Ang II was reported to be responsible for the hepatic fibrogenesis [Paizis et al 2001]. 
In addition, the pulmonary Ang II has been demonstrated to act as a potential 
profibrotic mediator in the lung via the activation of ATi receptor [Marshall et al 
2000]. Since Ang II is responsible for the most physiological and pharmacological 
effects of the RAS, the inhibitions of this system by RAS blockers such as ACE 
inhibitors and receptor antagonists for Ang II could produce beneficial effects from 
blocking the synthesis of Ang II. A fully understood of tissue-specific RAS could 
give rise to important clinical implications for a number of diseases. 
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1.2 RAS Inhibitors 
As the RAS plays important physiological and pathophysiological conditions, its 
inhibition could provide a therapeutic value for hypertension, myocardial infarction, 
cardiac failure, renal diseases, and tissue inflammation as well as diabetes. ACE 
inhibitor and Ang II receptor antagonists are the two most widely used RAS 
inhibitors (Fig. 1-2). More complete inhibition of the RAS would be definitely 
beneficial by virtue of using combination therapy of the two inhibitors. 
Vasodilation 
.(^^^^giotensinT^ Pain 
/ r Prostaglandin synthesis 
f \ Increased vascular permeability 
(^^^giotens inog^ 1 
ACE Inhibitor 
C S g i o t e n s i ^ j ^ Kininase I/II 
Non-specific Angll / • 
receptor blocker / T \ ： ： ^ ^ 
C J n ^ t i v e f r a g m e n t ^ 
ATi receptor antagonist AT2 receptor antagonist 
C ^ ^ T i r e c e p t o ^ - ^ - - ^ ^ r e c e p t o ^ 
t t 
Vasoconstriction Vasodilation 
Cell growth Anti-proliferation 
Superoxide generation Nitric oxide production 
Salt/water reabsorption P450 metabolites 
Aldosterone secretion Apoptosis 
Fig. 1-2 Schematic presentation of the RAS cascade with its relationship to ACE 
inhibitor and Ang II receptor antagonists. 
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1.2.1 Angiotensin converting enzyme inhibitor 
ACE is a bivalent dipeptidyl carboxyl metallopeptidase, which presents as a soluble 
form in blood and as a membrane-bound form in endothelial and epithelial cells of 
several organs. The ACE is a key enzyme in the RAS dedicated to convert the bio-
inactive Ang I into the effector peptide Ang II (Fig. 1-2). Cushman and Ondetti 
found that modification of carboxypeptidase inhibitor could block the activity of 
ACE and they made a revolutionary approach in 1975. They created the first orally 
active ACE inhibitor Captopril (Fig. 1-3 A) with the application of structure-based 
drug design technology. The FDA approved captopril in 1982 for the treatment of 
hypertension. Besides, ACE inhibitors were reported to attenuate myocardial 
infarction and cardiovascular diseases [Pfeffer et al 1988; Yusuf et al 2000]. 
The available ACE inhibitors can be divided into 3 groups: the sulphydryl-
containing group such as captopril and zofenopril, the carboxyl-containing group 
such as enalapril, quinapril and ramipril, and the phosphorous-containing group such 
as fosinopril and ceranapril [Wyvratt 1988; Voors et al 1995]. Generally, ACE 
inhibitors belonging to the carboxyl group are more potent than captopril but 
carrying lower bioavaliabilities while the phosphorous-containing group has longer 
duration of effectiveness. Some studies suggested that the sulphydryl-containing 
ACE inhibitors may act as free radical scavengers and provide beneficial effects on 
reperfusion-induced depression of contractility and arrhythmia [Pi and Chen 1989]. 
Ramiprilat, being utilized in this study, belongs to the carboxyl group and is a white 
crystalline drug modified with a hepatic cleavage of the ester group of ramipril (Fig. 
1-3A). ACE inhibitors are generally well tolerated by most individuals; however, 
some side effects such as persistent cough, diarrhea and rash may occur. In some 
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occasions, ACE inhibitors may cause angioedema, kidney and liver failure as side 
effects [Voors et al 1995]. 
The blockade of ACE could reduce the formation of Ang II; however, the 
ACE-independent mechanisms including chymase and cathepsin G systems may 
alternatively supply Ang II for completing the flow of the RAS cascade [Urata et al 
1996]. On the other hand, ACE is also known as kininase II, which participates in 
metabolizing bradykinin to inactive kinins in the kallikrein-kinin system (Fig. 1-2). 
The inhibition of ACE has been reported to produce elevation of bradykinin in 
plasma level. Bradykinin is a well-known vasodilator, pain producer and stimulator 
of prostaglandin synthesis [Bumier 2001]. The therapeutic effect of ACE inhibitors 
on bradykinin accumulation is still uncertain. 
1.2.2 Non-specific angiotensin II receptor blocker 
Since Ang II is the key active peptide of the RAS, saralasin is thought to be more 
effective than the actions of ACE inhibitor to block the RAS pathway more 
specifically at the last step, without worrying about the accumulation of bradykinin 
and the ACE-independent formation of Ang II (Fig. 1-2). Saralasin, which is a 
peptide-based analog of Ang II, is the first Ang II receptor antagonist developed in 
1971. The Asp-1 and Phe-8 residues of Ang II are replaced with Sar and lie 
respectively in saralasin and the chemical formula of saralasin becomes 
C42H65N13O10. Apart from saralasin, sarmesin and sarthran are also analogs of Ang 
II containing similar chemical structures. Saralasin acts as an antagonist for Ang II 
by competitively blocking both the ATi and AT2 receptors; however, it exhibits some 
unwanted partial agonist activities at high dose usage. Saralasin was found effective 
in treating hypertension in patients with high renin concentration, but not in patients 
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with low plasma level of renin [Satia et al. 1995]. In addition, saralasin has been 
reported to improve systemic hemodynamics in patients with congestive heart failure 
[Bumier 2001]. 
Since saralasin is a peptide-based antagonist, it has to be administrated 
parenterally. This characteristic has limited the clinical usefulness of saralasin. 
Other Ang II receptor blockers developed in the 90,s, such as EXP597 and XR510, 
also have equal binding affinities for both ATi and AT2 receptors; indeed, they have 
been improved with higher oral bioavailability and longer duration of action [Emm et 
al 1996]. Given that ATi and AT2 receptors may counteract to each other, if so, the 
blockade of RAS by saralasin could only represent the compensated results of the 
two receptor subtypes. To this end, the utilization of ATi receptor antagonist became 
more noteworthy. 
1.2.3 Specific ATi receptor antagonist 
The ATi receptor belongs to the seven transmembrane class of G-protein coupled 
receptor and is encoded by a 359-amino acid protein. Two isoforms, ATia and ATib, 
have been identified in rodents [de Gasparo et al. 2002]. The specific ATi receptor 
antagonist interacts with amino acids in the transmembrane region of the ATi 
receptor and occupies space among the seven helixes; thus prevents the binding of 
Ang II. Losartan potassium (DuPont pharmaceuticals, Dup 753; Merck and Co., MK 
954) is the first marketable non-peptide ATi receptor antagonist, which has been 
developed based on the modification of chemical structures of imidazoles S-8307 
and S-8308 [Timmermans et al 1993]. The “sartan’’ family including candesartan 
cilexetil, irebesartan and valsartan are biphenyl analogs of losartan (Fig. 1-3B) 
carrying different oral bioavailabilities, protein binding properties and acting 
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duration time. Losartan and candesartan cilextil are the only two compounds possess 
metabolites, and they are rapidly and completely converted to EXP-3174 and 
candesartan respectively [Goodfriend et al 1996]. 
Losartan overcomes the drawbacks of saralasin, that is to say improved with 
higher bioavailability, selective antagonism to ATi receptor and without exhibiting 
agonist effect in the course of RAS blockade. The ATi receptor antagonist was 
approved by FDA in 1995 for the treatment of hypertension, either alone or in 
combination with other antihypertensive agents. The application of ATi receptor 
antagonist has been reported to have fewer side effects than ACE inhibitors such as 
not causing persistent cough and angioedema, which are mediated by bradykinin 
[Satia et al. 1995]. However, similar to ACE inhibitors, the ATi receptor antagonist 
is also fetotoxic. In fact, most individuals generally tolerate the ATi receptor 
antagonist treatment very well. Nevertheless, CNS effects, back pain and diarrhea 
may still occur. Adverse effects such as hyperkalemia and upper respiratory tract 
infection may happen in atypical cases. 
1.2.4 Specific ATi receptor antagonist 
The binding affinity of Ang II with AT! receptor is similar to that of ATi receptor 
[de Gasparo et al 1995]. The AT! receptor also possesses a seven transmembrane 
domain but is encoded by a 3 63-amino acid protein. Only one isoform of AT2 
receptor has been discovered. In AT2 receptor-knockout mice, an increased 
vasopressor response to Ang II injection and an impaired drinking response to water 
deprivation were observed [Hein et al 1995]. In addition, the AT2 receptor-lacking 
mice had higher sensitivity to pain [Sakagwa et al 2000]. The results suggested that 
AT2 receptor might play a role in RAS-mediated cardiovascular and central nervous 
11 
system functions. In other studies, the AT2 receptor has been also suggested for 
mediating anti-proliferation, cellular differentiation and apoptosis [Dinh et al 2001]. 
For a better understanding of the functions of AT2 receptor, the application the 
specific AT2 receptor antagonist would be of assistance. A series of 1,2,3,4-
tetrahydrosioquinoline-3-carboxylic acids including EXP655, EXP801, PD121981, 
PD123317 and PD123319 have been developed with high binding affinities 
selectively to AT2 receptor for Ang II. The PD 123319-ditrifluoroacetate is a 
commonly used non-peptide AT2 receptor antagonist, which is industrialized by the 
Parke-Davis Pharmaceutical Research (Fig. 1-3C). PD121981 (WL-19), PD123177, 
EXP801 and EXP655 are the former versions of PD 123319 containing similar base 
chemical structures. The peptide ligands CGP42112A and /?-aminophenylalanine6-
Ang II are found to act as agonists for the AT2 receptor [Timmermans et al. 1992]. 
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Fig. 1-3 Commonly used RAS inhibitors and their chemical structures. 
(A) ACE inhibitors: captopril and ramipril. (B) ATi receptor antagonists: losartan 
and candersartan cilexetil. (C) AT! receptor antagonists: PD123317 and PD123319. 
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1.3 Pancreas and functions of exocrine pancreas 
1.3.1 Structure of pancreas 
Pancreas is a flat and elongated gland associated with the upper duodenum (Fig. 1-
4A). It consists of a head, a body and a tail, and is grouped into lobules by reticular 
septae. The main pancreatic duct, with connections to interlobular and intralobular 
ducts, runs through the whole length of the gland and empties into the upper 
duodenum at duodenal papilla. Indeed, the pancreas carries both exocrine and 
endocrine functions. The exocrine functions are carried out by the pancreatic acini 
and ductal epithelia. The pancreatic acini are composed of columnar to pyramidal 
epithelial cells with minimal stroma and contain well-developed Golgi complex (Fig. 
1-4B). The acinar cells form apically oriented complex with zymogen granules 
containing digestive enzymes. Those zymogen granules migrate to the apical plasma 
membrane in order to release its contents into the lumen in response to hormonal or 
neuronal stimulation. Centroacinar cells are located at the junctions between 
intercalated ducts and acini, and believed to serve as signal transducers for regulating 
the degranulation of acinar cells. The exocrine acini are densely packed throughout 
the pancreas and connected by intercalated ducts, interlobular ducts and the main 
pancreatic duct to form an extensive network for the organ. The squamous ductual 
epithelial cells are located at different types of ducts in the pancreas and participating 
in bicarbonate and water secretions [Gray 1918]. 
The pancreatic endocrine action is performed by the islets of Langerhans, 
which are round, compact and highly vascularized with scanty connective tissue (Fig. 
1-4B). The endocrine subunit is composed of small spheroid cluster of cells, namely 
a, p, 5 and PP cells. The a cells are responsible for producing glucagons, (3 cells for 
insulin, 6 cells for somatostatin and PP cells for pancreatic polypeptides. The islets 
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are distributed throughout the pancreas, which consist of about 5 % of the total 
pancreatic mass; whereas the acinar cells make up most the pancreas. The exocrine 
secretions are released through the pancreatic duct into the duodenum for proper 
digestions of food while the endocrine subunit discharges insulin and glucagon 
directly into the bloodstream for blood glucose homeostasis. 
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Fig. 1-4 Structure of pancreas 
(A) Overview of the pancreas. (B) Histological examination (H&E staining) of the 
rat pancreatic tissue. (Magnification x 400) 
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1.3.2 Exocrine secretions and pancreatic enzymes 
Most of the essential enzymes in the gastrointestinal tract required for digestion are 
secreted from the exocrine pancreas. Besides, bicarbonate and water are also the 
major secretory products of the exocrine gland. The bicarbonate and water secreted 
by the pancreatic ductal cells neutralize the gastric acid before entering the 
duodenum and provide an optimal alkaline condition for the activation of various 
pancreatic digestive enzymes, including a-amylase, lipase, proteases, ribonuclease 
and deoxyribonuclease, which are secreted by the acinar cells. Most of the 
proteolytic enzymes are packaged as inactive precursor zymogens, such as 
chymotrypsinogen and trypsinogen, in order to prevent the pancreatic self-
destruction. In addition, trypsin inhibitors are present in the ductal and acinar 
secretions for stabilizing the proteolytic enzymes from mopping up any active trypsin. 
The trypsinogens are activated into trypsin only in the duodenum by membrane-
bound enterokinases. Other zymogens are then activated in response to the intra-
pancreatic release of trypsin and become active endopeptidases to carry out the 
breakdown of proteins into polypeptides or amino acids. The major dietary 
carbohydrate, starch, is hydrolyzed by the actively secreted a-amylase, and is 
converted into trisaccharide, maltose and dextrins. The pancreatic lipase breaks 
down the major dietary fat, triglyceride, into glycerides and free fatty acids. The 
ribonuclease and deoxyribonuclease are also secreted in active forms and they are 
responsible for breaking down nucleic acids (RNA and DNA) into nucleotides. 
Sufficiency of pancreatic exocrine secretion is essential for efficient digestion of 
food, and the subsequent normal absorption [Singer 1993; Hoist 1993]. 
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1.3.3 Regulation of exocrine secretions 
Exocrine secretions of the pancreas are regulated in response to the food taken into 
the gastrointestinal system. When all the food is emptied from the gastrointestinal 
system, a certain level of exocrine secretion still occurs and that is considered as the 
basal secretion. The basal pancreatic secretion could be mediated through the very 
low circulating levels of cholecystokinin (CCK) and secretin, as well as the 
metabolically dependent secretion of enzymes from the acinar cells. The food-
induced exocrine secretion is modulated by both neural stimulations and hormonal 
controls. Neurotransmitters from pancreas, gut and vagus nerve contribute to the 
neural control of the exocrine secretion regulation. In addition, number of studies 
showed that acetylcholine released from the intrapancreatic postganglionic 
cholinergic neurons acts directly on acinar and ductal cells in order to regulate the 
exocrine secretions, so as the vasoactive intestine peptide from peptidergic nerves 
[Solomon 1994; Chey and Chang 2001]. On the other hand, CCK, secretin and 
gastrin are the three important gastrointestinal hormones responsible for controlling 
the pancreatic exocrine secretions. In response to the small peptides and fatty acids 
in small intestine, the synthesis of CCK by the endocrine I cells of duodenum is 
highly stimulated and CCK is then released into the bloodstream. As CCK binds to 
its receptors on pancreatic acini, large quantity of digestive enzymes is secreted from 
the pancreas into the lumen of duodenum [Rosewicz et al. 1989]. As the release of 
hormone secretin is rapidly increased in response to gastric acid in the duodenum, 
the exocrine pancreas is modulated to secrete bicarbonate and water in order to be 
cooperative with the elevated secretion of digestive enzymes. Gastrin is a hormone 
released by stomach in response to food stimuli. Similar to CCK, it also induces 
secretion of digestive enzymes from the pancreas [Grant 2001]. Besides the classical 
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neuronal and hormonal controls, many regulatory factors such as cytokines, 
prostaglandin and vasoactive peptides are found to stimulate exocrine pancreatic 
secretion of bicarbonate and digestive enzymes. The vasoactive peptide Ang II has 
been demonstrated to play a role in stimulating the a-amylase secretion in the AR42J 
acinar cell line [Cheung et al. 1999]. Indeed, the pancreatic endocrine hormones 
such as glucagon, somatostatin and pancreatic polypeptide are factors for inhibiting 
the exocrine secretion of pancreas. The vital role of exocrine pancreas is manifested 
with the fact that the insufficiency in pancreatic exocrine secretion as occurred in 
pancreatitis leads to maldigestion and malabsorption of our body. 
1.4 Pancreatic RAS 
1.4.1 Expression and localization 
Most of the early studies of tissue RAS were focused on the vascular, cardiac and 
renal levels. Recently, a wide range of tissues and organs has been investigating 
steadily in the past two decades. Majority of tissues were found to express primarily 
the Ang II type 1 receptor. However, the pancreas possesses a dominant amount of 
the AT2 receptor subtype [Leung and Chappell 2003]. Expression of Ang II as well 
as its metabolites Ang III and Ang 1 -7 were documented within the canine pancreas 
[Chappell et al. 1991]. The characterization of key RAS components in pancreatic 
tissue has been reported in a variety of species, including canine, [Chappell et al 
1991], rat [Ghiani & Masini 1995; Leung et al. 1999], mouse [Leung et al. 1998] and 
human [Tahmasebi et al 1999]. In rat pancreas, gene expressions of RAS 
components including renin, angiotensinogen and Ang II receptors, and the 
localization of angiotensinogen protein have been well demonstrated [Leung et al. 
1997, 1999]. All these results could consolidate the existence of a pancreatic RAS. 
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By means of autoradiography, Ang II receptors were shown to be present in both 
acinar and islet cells [Chappell et al. 1992, 1995]. By means of the in-situ 
hybridization and immunohistochemistry techniques, angiotensinogen and Ang II 
receptors (ATi and AT2) have been shown to localize primarily in the epithelia of 
pancreatic ducts and the endothelia of vasculature [Leung et al 1997, 1999]. In rats, 
two isoforms of ATi receptor, ATia and ATib, were detected in the RT-PCR analysis 
and the ATia was found to be the predominant isotype present in pancreatic tissue 
[Leung et al 1999]. Taken together, all these data from expression and localization 
studies support the existence of an intrinsic RAS in the pancreas, which may be of 
importance in the regulation of pancreatic exocrine as well as endocrine functions. 
1.4.2 Regulation 
It is known that the expression of major RAS components is regulated by multiple 
factors of physiological and clinical aspects including hormones, electrolytes, 
hypoxic stress and pathological conditions [Phillips et al 1993]. The same principle 
should apply to the pancreatic RAS. Recent studies demonstrated that the pancreatic 
RAS has been up-regulated in rat models under the treatments of experimental 
pancreatitis [Leung et al. 2000; Ip et al. 2003] and chronic hypoxia [Chan et al 2000; 
Ip et al 2003]. RAS components, notably angiotensinogen and Ang II receptors 
(both ATi and AT2) in the mRNA and protein levels were elevated in a significant 
amount in pancreatitis and chronic hypoxia models when compared to their 
respective controls. In addition, the pancreatic RAS has been also subjected to 
regulation by pancreatic endocrine tumors (PET). In that study, the gene expressions 
of AT2 receptor and angiotensinogen were significantly increased whereas the 
mRNA for ATi receptor was decreased in human PET samples [Lam and Leung 
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2002]. In view of these observations, the localization, expression and regulation of a 
pancreatic RAS may have physiological and pathophysiological consequences in the 
exocrine and endocrine pancreas. 
1.4.3 Clinical Relevance to the pancreas 
Emerging data on the expression and localization of key RAS components, 
particularly angiotensinogen, ATi and AT2 receptors, have provided solid evidence 
for the existence of an intrinsic, angiotensin-generating system in the pancreas. This 
tissue RAS may play a potential role in regulating exocrine and endocrine functions 
of the pancreas such as acinar secretion of digestive enzymes and islet hormonal 
secretion. Interestingly, the pancreatic RAS is responsive to a number of 
physiological and pathophysiological stimuli. These include chronically hypoxic 
condition and during several other clinical conditions, e.g. acute pancreatitis and 
endocrine tumor. The significance of tissue RAS in the pancreas and its regulation 
by pancreatitis and hypoxia could be of potential importance in the physiology and 
pathophysiology of the pancreas. The target for the inhibition of pancreatic RAS by 
virtue of using specific RAS inhibitors could provide an insight into several exocrine 
and endocrine pancreatic diseases such as acute pancreatitis, pancreatic cancer, 
diabetes mellitus and cystic fibrosis. The pancreatic RAS could also have 
implications for pancreatic islet transplantation [Leung and Carlsson 2001]. 
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1.5 Acute pancreatitis 
1.5.1 Pathogenesis 
Acute pancreatitis is an inflammatory disease of the pancreas, which happens as a 
sudden onset. It is believed to be a result of an inappropriate activation of proteolytic 
zymogens occurred within the pancreatic acinar cells. The pre-mature activation of 
trypsin, which is restored from trypsinogen through the proteolytic cleavage of the 
N-terminal peptide trypsinogen-activating peptide (TAP), is thought to be the initial 
event in the evolution of pancreatitis [Neoptolemos et al. 2000]. The lysosomal 
hydrolase cathepsin B has been suggested to activate trypsinogen when trypsinogen 
is erroneously co-localized with cathepsin B in the cytoplasmic vacuoles, thus 
causing its premature activation [Steer 1998]. Other inactive zymogens, such as 
procarboxypeptidase Al, procarboxypeptidase B and chymotrypsinogen 2 packaged 
in the secretory granules, are impulsively activated by trypsin in a cascade reaction 
within the pancreatic acini and restored into proteolytic enzymes. The abnormally 
activated zymogens escape into the interstitium of the pancreas and lead to the 
disruption of acinar cells, thus the autodigestion of the gland [Gorelick et al. 1992]. 
The proteolysis of zymogens within pancreatic acini has been demonstrated as an 
association with acinar cell damage [Grady et al. 1998]. Besides, high doses of CCK 
have been shown to stimulate intracellular activation of zymogens within isolated 
pancreatic acini [Leach et al 1991]. Activation of the inflammatory cascade is also 
considered to be involved in the pathogenesis of acute pancreatitis. Cytokines, free 
radicals and nitric oxide are participating in the progression of the disease [Mitchell 
et al 2003]. In fact, gallstone and alcoholism are the common leading causes of 
acute pancreatitis. In addition, the cationic trypsinogen gene has been identified to 
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cause hereditary pancreatitis and the development of recurrent acute pancreatitis 
[WhitcomWfl/. 1996]. 
1.5.2 Experimental models of acute pancreatitis 
Intraperitoneal injection of CCK secretagogue, cerulein, is the most widely used 
method for the production of an experimental acute pancreatitis in animal models by 
means of hyperstimulating the pancreatic secretion of digestive enzymes [Lampel 
and Kem 1977]. A supramaximally stimulating dose at 50 }ig/kg/hr is used for 
inducing a mild edematous pancreatitis in an experimental period varying from one 
to twelve hours [Kaiser et al 1995]. In addition to the well-established method of 
cemlein-induced acute pancreatitis, other models such as pancreatic bile duct 
occlusion, intra-ductal infusion with sodium taurocholate, glycodeoxycholic acid and 
digestive enzymes are also commonly used for the induction of pancreatitis. With 
regard to the induction of a severe form of acute pancreatitis with necrosis and 
hemorrhage, the biliopancreatic duct could be retrogradely infused with bile salts or 
acids including sodium taurocholate (5 %) and glycodeoxycholic acid (10 mmol/L) 
for 10 to 20 minutes and generally followed by a continuous intravenous infusion of 
cerulein (5 昭/kg/hr) for 6 hours [Nevalainen and Aho 1992]. Intra-ductal infusion 
with digestive enzymes such as trypsin (3 |ig/kg/h) and enterokinase (30 U/kg/h), 
partial occlusion of pancreatic bile duct and continuous regional arterial perfusion of 
the pancreas with isotonic saline are also frequently utilized for inducing 
experimental pancreatitis in animals [Kaiser et al. 1995]. In addition, pancreatitis 
could also be initiated by ischemia, free fatty acid infusion and ethionine-
supplemented diet in order for the production of a moderate form of pancreatitis 
[Sanfey et al 1985]. 
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1.5.3 Criteria for acute pancreatitis 
As the pancreas is damaged, amylase and lipase would escape from the tissue and 
rush into the bloodstream, thus plasma hyperamylasemia and hyperlipasemia are two 
primary biochemical indicators for the diagnosis of acute pancreatitis [Clavien et al 
1989]. However, normal level of plasma a-amylase may occur occasionally in 
pancreatitis. Furthermore, hyperamylasemia could be associated with other 
extrapancreatic diseases, such as acute cholecystitis, small bowel obstruction and 
peptic ulcers [Clavien et al 1989]. Similarly, hyperlipasemia may also be observed 
in chronic or acute renal disease. Therefore, the simultaneous measurements of both 
a-amylase and lipase are often performed in order to supplement the diagnosis of 
acute pancreatitis. Since the serum lipase level is found to stay elevated longer than 
the serum amylase, it is believed that serum lipase would be helpful in the late 
detection of acute pancreatitis. In addition, plasma level of pancreatitis-associated 
protein (PAP) has been also utilized clinically to diagnose and monitor the evolution 
of acute pancreatitis. The mRNA for secretory protein PAP is almost absent in 
normal pancreas but is found to be overexpressed in the acute pancreatitis-induced 
pancreatic tissue [Su et al 1999]. Furthermore, the serum level of trypsinogen 2, 
which is the anionic isoenzyme of trypsinogen, could represent a correlation to the 
severity of the disease [Hedstrom et al. 1996]. On the other hand, morphological 
features such as interstitial edema, acinar cell damage, fat necrosis, infiltration of 
macrophage and hemorrhage are often characterized for the development of acute 
pancreatitis [Spormann et al. 1989]. Histological tissue sections that show interstitial 
edema and peripancreatic fat necrosis can be described as mild acute pancreatitis 
whereas those display parenchymal necrosis and hemorrhage are regarded as severe 
forms. Release of toxin factors into the systemic circulation is often associated with 
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severe acute pancreatitis. Severity of experimental acute pancreatitis could be 
defined according to the morphological alterations or the grading of necrotic 
parenchyma [Friess et al 1992]. 
1.5.4 Oxidative stress in acute pancreatitis 
Oxidative radicals have been suggested to play a significant role in the evolution of 
experimental acute pancreatitis, leading to oxidative stress, and consequently causing 
inflammation and tissue injury [Sanfey et al. 1984]. Oxidative-derived free radicals 
are the normal side-products of metabolism, and they are immediately removed by 
the anti-oxidant system in normal condition. Majority of the radicals are originated 
from oxygen and nitrogen, so they are termed reactive oxygen and reactive nitrogen 
species respectively. However, oxidative stress develops when the production rate of 
free radicals overwhelms the homeostasis. The intracellular formation of reactive 
oxygen species such as superoxide anion, hydroxyl free radical and hydrogen 
peroxide could cause inflammation and cellular injury in pancreatic acini during the 
course of acute pancreatitis [Schonberg et al. 1994] (Fig. 1-5). Enzymatic radical 
scavengers such as GSH peroxidase and superoxide dismutase are regarded as the 
primary defense against the reactive oxygen species. The reduced-glutathione level 
in pancreatic tissue was rapidly depleted by GSH peroxidase after the onset of acute 
pancreatitis [Neuschwander-Tetri et al 1992]. In addition, the reactive oxygen 
species have been reported to attack membrane lipids and proteins thus causing the 
formations of thiobarbituric acid-reactive substance malondialdehyde (MDA) and 
protein carbonyls, which are the direct markers respectively for lipid peroxidation 
and protein oxidation [Reinheckel et al. 1999]. Moreover, the expression of 
oxidative stress-response genes, including c-fos, heme oxygenase-1 and 
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metallothionein-I, was significantly enhanced in the cerulein-induced pancreatic 
tissue [Sato et al 1997; Fu et al 1997]. Transgenic mouse overexpressing with the 
Cu2+/Zn2+-superoxide dismutase gene was found to significantly reduce the elevated 
levels of serum a-amylase and lipase in animals with acute pancreatitis [Kikuchi et 
al 1997]. These results showed that the involvement of reactive oxygen species in 
the pathogenesis of acute pancreatitis could be assessed in terms of the generation of 
oxidative products. Furthermore, the activities of reactive oxygen species and 
production of oxidative products are found directly proportional to the severity of 
cerulein-induced acute pancreatitis [Dabrowski et al. 1999]. The conversion of 
molecular oxygen to superoxide anion is believed to be the initial step for the 
formation of reactive oxygen species, and the membrane-bound NADPH oxidase 
system is the major potential source of the superoxide anion generation [Parks 1989]. 
In rat aortas, endogenous Ang II was demonstrated to activate NADPH oxidase as 
implicated by the increase in reactive oxygen species formation [Heitzer et al. 1999]. 
Indeed, acute pancreatitis is a mild and self-limited disorder; however, it may also be 
severe to an extent of mortal systemic inflammation thus causing multiple organ 
dysfunction syndromes [Debeaux et al 1995; Tenner et al 1997]. 
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Fig. 1-5 Schematic presentation of pathophysiological relevance of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS). 
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1.6 RAS and acute pancreatitis in exocrine pancreas 
1.6.1 RAS and acute pancreatitis 
Although the cause of acute pancreatitis is multifactorial, some of the crucial factors 
may include the activation of proteolytic enzymes, lipase, kinins and other vasoactive 
peptides such as Ang II [Agarwal and Pitchumoni 1993; Lembeck and Griesbacher 
1996]. In fact, it was previously reported that the plasma renin was significantly 
activated in acute pancreatitis, suggesting a role of RAS in the evolution of acute 
pancreatitis [Barrett et al 1982; Greenstein et al 1987; Pitchummoni et a/. 1988]. 
However, the association between acute pancreatitis and RAS, in particular emphasis 
on a tissue RAS in the pancreas, has received scant attention in the literature. 
Previous studies in our laboratory indicated that the pancreatic RAS was up-
regulated in the rat model of experimental acute pancreatitis, as implicated by the 
activation of major RAS components in both mRNA and protein levels in pancreatic 
tissue [Leung et al 2000]. In this regard, pancreatic ACE activity was extensively 
increased approximately 6 folds in the course of acute pancreatitis [Ip et al. 2003]. 
These results gave an integral view of the up-regulation of pancreatic RAS in the 
evolution of an experimental acute pancreatitis. To this end, blockade of the 
pancreatic RAS with ACE inhibitors and Ang II receptor antagonists could confine a 
deeper investigation and confirmation of the interaction between the tissue RAS and 
acute pancreatitis. 
1.6.2 RAS and pancreatic microcirculation 
Vasoconstriction, leukocyte adherence, changes in capillary permeability and 
hemorrhaging alterations are the major disturbances affecting the microcirculation of 
the pancreas [Zhou and Chen 2002; Chen et al. 2001]. Besides, the intra-pancreatic 
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ductal pressure may be also influenced by the activation of the pancreatic RAS 
during the course of acute pancreatitis. Number of works showed that RAS could 
play a regulatory role in the generation of reactive oxygen species [Dabrowski et al. 
1999]. The Ang Il-mediated generation of reactive oxygen species in the 
microenvironment of pancreatic duct may lead to the changes in the permeability of 
capillary. In addition, leukocyte adherence may be initiated by lipid peroxidation, 
thus causing changes in the permeability and impairment of capillary [Menger et al 
2001]. Therefore, a local RAS in the pancreas is believed to have modulating 
capability in the generation of reactive oxygen species, thereby the pancreatic 
microcirculation. On the other hand, activation of the pancreatic RAS occurs during 
the exposure to some forms of stress, such as cardiogenic [Reilly et al 1997], septic 
[Oldner et al. 1999] or trauma [Kincaid et al 1998] shocks. In cardiogenic shock, a 
selective Ang Il-mediated pancreatic vasoconstriction is seen that causes severe 
pancreatic ischemia/hypoxia [Reilly et al 1997]. In this regards, splanchnic blood 
perfusion is markedly improved following an Ang II receptor antagonism [Kincaid et 
al. 1998; Oldner et al 1999]. Recently, it has been shown that infusion of Ang II 
induced a dose-dependent reduction in both whole pancreatic and islet 
microcirculation [Carlsson et al 1998]. In that study, administration of ACE 
inhibitor and Ang II receptor blocker could increase the pancreatic circulation. 
1.6.3 RAS and tissue injury 
Recent studies have demonstrated the effect of Ang II in stimulating the synthesis 
and secretion of vascular permeability factor. This in turn leads to cell infiltration 
and exudation plasma macromolecules [Pupilli et al. 1999; Williams et al 1995]. 
Ang II has also been shown to stimulate the synthesis of adhesion molecules and 
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chemokines [Scheiffer et al. 2000] as well as the migration and adhesion of 
monocytes and leukocytes [Kintscher et al. 2001; Alvarez and Sanz 2001]. These 
data indicate that RAS plays a critical role in the formation of tissue inflammation 
and disease injury. A number of recent studies demonstrated that blockade of 
intrinsic RAS could attenuate injury in local tissues and organs. Gene and protein 
expressions of major RAS components are found to be up-regulated in diseased liver 
parenchyma of the bile duct-ligated rats. The antifibrotic effects of RAS blockade 
implicated the participation of the local RAS in fibrogenic responses in liver [Paizis 
et al 2002]. In addition, the administration of Ang II receptor blocker has been 
shown to produce beneficial effects on the postischemic endothelial dysfunction in 
isolated working rat heart [Barsotti et al 2001]. Pulmonary RAS has been 
demonstrated to play a role in the increasing of fibroblast activity and vascular 
permeability. Both ACE inhibitor and Ang II receptor antagonist are reported to 
attenuate experimental lung injury [Marshall 2003]. Since Ang II is found to induce 
vascular damage and cardiovasvular diseases through mediating the production of 
chemokines, cytokines and adhesion molecules [Ruiz-Ortega et al 2001], the 
applications of RAS inhibitors could be of assistance in studying the role of local 
RAS in tissue injury. 
1.6.4 Exocrine pancreatic RAS and acute pancreatitis-induced injury 
Expression of RAS components has been recently reported in the AR42J acinar cell 
line [Chappell et al. 1995]. The mRNA and protein levels of major RAS 
components in pancreatic tissue are increased significantly in the evolution of acute 
pancreatitis [Leung et al 2000]. More interestingly, the pancreatic inflammation and 
fibrosis caused by chronic pancreatitis could be attenuated by administration of ACE 
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inhibitor [Kuno et al 2003]. This result further supports the involvement of RAS in 
pancreatits-induced injury. Emerging data from different aspects implicated the 
existence of a local RAS in the exocrine acini and such a system would be expected 
to be up-regulated by acute pancreatitis as seen in the pancreatic tissue. The 
applications of RAS inhibitors should have some beneficial effects against acute 
pancreatitis-induced tissue injury as well as the acute pancreatitis-associated 
systemic inflammation. 
1.7 Aims of study 
Based on the available information, the present study is designed specifically to 
investigate the effects of RAS inhibitors on acute pancreatitis-induced pancreatic 
injury and the potential role of RAS in exocrine pancreas. Therefore, the aims of 
present study are set as follows: 
• Biochemical analysis of RAS inhibitors on the changes in acute pancreatitis-
induced pancreatic injury and oxidative stress 
• Histopathological analysis of RAS inhibitors on the pancreatic histology in acute 
pancreatitis 
• Potential role of RAS in exocrine acinar secretion 
• Existence of RAS and its regulation by acute pancreatitis in acinar cells 
• Potential role of RAS in acute pancreatitis 
• Preliminary study of RAS in acute pancreatitis-induced systemic inflammation 
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Chapter 2 Materials and Methods 
2.1 Animal Models and RAS inhibitors 
Male Sprague-Dawley (SD) rats aged 28 days weighing in the range of 75 to 100 grams 
were used in all experiments. The animals were bred in the Laboratory Animal Services 
Center of the Chinese University of Hong Kong, fed with standard rat chow, and 
supplied with water ad libitum. The rats were housed under a 12-hour light/dark cycle 
with constant ambient temperature of 2 2 � � ± 1 � � a n d relative humidity in the range of 
60 to 80 %. Ethical approval for experimental procedures has been obtained from the 
Animal Ethical Committee of the Chinese University of Hong Kong. The animals were 
subjected to pentobarbital-anesthetic management during the whole period of 
experiment and were killed by cardiac excision. 
Four RAS inhibitors were used in the present study. The non-specific Ang II 
receptor ligand saralasin and the specific ATi receptor antagonist PD123319 were 
purchased from Sigma Co., USA. The specific ATi receptor antagonist losartan and the 
ACE inhibitor ramiprilat were received as gifts from Merck, USA and Aventis, 
Germany respectively. 
2.1.1 Cerulein-induced acute pancreatitis 
Prior to the experiments, the SD rats were starved overnight but allowed with free 
access to water. Animals were randomly assigned to acute pancreatitis group and 
control group. In the acute pancreatitis group, the rats were treated with CCK-
secretagogue, cerulein (Pharmacia GmbH, Germany), for the induction of disease 
[Lampel and Kem 1977]. A time-course experiment was performed in order to figure 
out the minimum time required for the onset of acute pancreatitis. A single intra-
peritoneal (i.p.) injection of cerulein was given at 50 i^g per kilogram of body weight to 
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animals at minute 0 and if applicable one more at minute 60. The control did not 
receive any cerulein injection. Two-hour was chosen as the intending experimental 
period for development of acute pancreatitis. During the 2-hour experimental period, 
two i.p. injections of cerulein were given hourly to animals in the acute pancreatitis 
group. A supramaximal stimulating dose was given at 50 |ag/kg/hr in order to construct 
a mild edematous pancreatitis. The second injection of cerulein was given to the animal 
60 minutes after the first injection, and the animal was sacrificed 60 minutes thereafter. 
Rats in the control group received 0.9 % NaCl saline solution injection instead of 
cerulein in same volume and at same time intervals. The experimental protocols for the 
induction of acute pancreatitis and the treatment with RAS inhibitors were summarized 
in Table 2-1. 
2.1.2 Prophylactic treatment with RAS inhibitors 
Animals were randomly assigned to 4 groups, acute pancreatitis, acute pancreatitis + 
prophylactic treatment (AP + PT), control and placebo (placebo PT). All four 
experimental groups were handled the same during the 2-hour experimental period as 
mentioned in section 2.1.1, except that rats in both AP + PT and placebo PT groups 
were pre-treated with RAS inhibitors (ramiprilat, saralasin, losartan or PD123319) 30 
minutes prior to the first i.p. injection of cerulein. RAS inhibitor was given as an 
intravenous (i.v.) injection to the tail vein of the rat model. All animals were sacrificed 
120 minutes after the first cerulein injection (Table 2-1). Saralasin and ramiprilat were 
given to animals at doses in the range of 5 to 40 ^ig/kg whereas losartan and PD 123319 
were given to animals at doses in the range of 50 to 800 |ag/kg. 
31 
2.1.3 Therapeutic treatment with RAS inhibitors 
Animals were randomly assigned into 4 groups, acute pancreatitis, acute pancreatitis + 
therapeutic treatment (AP + TT), control and placebo (placebo TT). All four 
experimental groups were handled the same as mentioned in the previous section, 
except that the AP + TT and placebo TT groups were intravenously injected with RAS 
inhibitor 30 minutes after the second cerulein injection during the 2-hour experimental 
period. All animals were sacrificed 120 minutes after the first injection of cerulein 
(Table 2-1). Dosages of inhibitors were given as the same as in the prophylactic 
treatment groups. 
Prophylactic and therapeutic treatments with RAS inhibitors 
^ ^ ^ ^ TimeO Time 30 Time 60 Time 90 Time 120 Time 150 
“ 7 1 0.9%NaCl “ 0.9%NaCl ^ 
Control N/A (i.p.) N/A (i p ) N/A Killed 
, Cerulein ../A Cerulein , . 丁 , 
AP N/A 二 1 N/A 二 N/A Killed 
Placebo ||RAS(i.v.) 0.9%NaCl 0.9%NaCl ^ ^ Killed 
PT Inhibitor q^O N/A (j.p.) N/A Jellied 
AP+PT n /A N/A Killed Inhibitor (i.p.) (i.P.) 
Placebo 0.9%NaCl ^ 0.9%NaCl RAS (i.v.) 丁,.” ^ ^ 
TT (Z.) N/A (i；.) Inhibitor Killed N/A 
Cerulein , Cerulein RAS (i.v.) 丁,.” j � t / a AP+TT M/A 广、 T 1 ‘ Killed N/A 
八 丄 (i.p.) 丄�'八 （i.p.) Inhibitor 
Table 2-1 Summary of the time schedule for prophylactic and therapeutic treatments; 
PT: prophylactic treatment, TT: therapeutic treatment, N/A: not applicable. 
2.2 Evaluation of pancreatic injury 
Tissue injury is one of the distinguished consequences of acute pancreatitis. Formation 
of pancreatic edema, hyperamylasmia and hyperlipasmia are the primary indicators of 
the acute pancreatitis-induced pancreatic tissue injuries [Clavien et al 1989; Nevelainen 
and Aho 1992]. 
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2.2.1 Assessment of pancreatic water content 
Pancreatic edema results from the gain of water content in acute pancreatitis-induced 
pancreatic tissue. This can be reflected by the gain of tissue weight. Pancreatic tissue 
was removed, freed from fat and blotted dry. Weights of each animal and its pancreatic 
tissue were measured. The obtained weights were expressed as a ratio of pancreatic 
weight to body mass (g/kg) in order to assess the formation of pancreatic interstitial 
edema. 
2.2.2 Measurement of a-amylase activity in plasma 
Traditionally, the diagnosis of acute pancreatitis is based on the elevation of serum 
amylase activity [Clavien et al. 1989]. Heparinized blood sample was drawn from 
anesthetized animal by cardiac puncture and plasma was obtained by centrifuging the 
whole blood at 2,000 x g at 4 � C . The activity of a-amylase in plasma was measured 
with an assay kit from Sigma Co., USA by following the manufacturer's instruction. 
Briefly, the activity was measured based on the hydrolytic rate of a-amylase in 
hydrolysis of the substrate 4,6-ethylidene-G7-p-nitrophenol to G2, G3 and G4 fragments 
and further to j9-nitrophenol and glucose, using a kinetic spectrophotometric method. 
The reaction started once 4 jil of plasma sample was added to 200 |LI1 of the substrate 
reagent at 37 °C. The increase in light absorbance of p-nitrophenol at 405 nm in a 2-
minute period was taken with the micro-plate reader (Bio-tek Instrument Inc., USA). 
The rate of increase was calculated and the enzyme activity was expressed as U/L. 
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2.2.3 Measurement of lipase activity in plasma 
Another diagnostic parameter for acute pancreatitis is the elevation of serum lipase 
activity, which is believed to remain elevated longer than serum amylase [Clavien et al. 
1989]. Plasma samples were obtained as mentioned in the previous section. The 
activity of lipase was measured based on a colorimetric method using the Lipase-PS 
assay kit from Sigma Co., USA. By following the manufacturer'S instruction, 10 |LI1 of 
plasma sample was incubated with 90 \i\ of reconstituted substrate solution at 37 °C for 
4 minutes allowing the pancreatic lipase to hydrolyze the substrate 1,2-diglyceride to 
monoglyceride and fatty acid. Upon the addition of 30 i^l of activator solution, the 
mixture was incubated for another 3 minutes at 37 A quinone diimine dye was 
formed, which absorbs light at 550 nm. Readings were taken with the micro-plate 
reader and the rate of increase in absorbance at 550 nm was used in calculating the 
pancreatic lipase activity, which was expressed as U/L. 
2.3 Histopathological examinations 
Acute pancreatitis is morphologically characterized by acinar cell damage, interstitial 
edema, parenchymal necrosis and hemorrhages. All these morphological alterations 
could be examined through histological slides under light microscopy. Acinar cell 
damage can be defined as cytoplasmic vacuolization or shrinkage. The interstitial 
edema could be determined by measuring the expansion area developed in interlobular 
space of the pancreatic parenchyma. Loss of membrane integrity and disintegration of 
organelles are morphological markers for parenchymal necrosis [Nevalainen and Aho 
1992]. 
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2.3.1 Preparation of paraffin blocks 
Pancreatic tissues were harvested, trimmed from fat and fixed in 4% (w/v) 
paraformaldehyde (PFA) at 4 overnight. The PFA-treated tissues were further 
processed in a tissue-processing machine for 18 hours with repeated sequential ethanol 
dehydrations and xylene clearing procedures. Processed tissue samples were embedded 
in molten paraffin and cast into blocks after cooling. 
2.3.2 Hematoxylin and eosin staining 
Paraffin-embedded tissue blocks were sectioned into 5 [im slices using the biocut rotary 
microtome machine (Reichert-Jung, Germany). The sliced pieces were transferred to a 
4 0 � C water bath and allowed floating out. After trimming, the slices were fixed onto 
0.5 % gelatin-coated slides and allowed to dry. The slides holding the sectioned tissues 
were de-paraffinized with xylene 3 times, and hydrated with 100 %, 90 %, 80 % and 70 
% ethanol in a series (Table 2-2A). After rinsing with water, the sections were stained 
with hematoxylin and eosin (H&E) for 8 minutes and 2 minutes respectively. A brief 
rinsing with 1 % acid alcohol and Scott's tap water was done in between the 2 staining 
steps. The cytoplasm was stained red with eosin while the nucleus was stained blue 
with hematoxylin (Table 2-2B). The stains were sequentially fixed with a series of 
graded ethanol, 70 %, 80 %, 90 % and 100%. The fixing was further enhanced with 
xylene. The H&E stains were mounted on the sections using the Clearmount solution 
and covered up with transparent slips (Table 2-2C). The stained slides were examined 
under light microscope (Leica, Germany) at magnification of 400 x. Images were 
captured using the Leica DC200 software. 
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De-paraffinize the tissue sections: 
Reagents: Time: 
Xylene 5 minutes 
Xylene 5 minutes 
Xylene 5 minutes 
100% ethanol 3 minutes 
90% ethanol 3 minutes 
80% ethanol 3 minutes 
70% ethanol 3 minutes 
ELinse with water briefly 
Table 2-2A Summary of the de-paraffmization procedures 
Stain sections with H&E: 
Regents: Time: 
Hematoxylin ？里！^"：进 fs 
1 % acid alcohol 10 seconds 
Scott's tap water 15 seconds 
Eosin 2 minutes 
Rinse with water briefly 
Table 2-2B Summary of the H&E staining procedures 
Fix stained sections: 
Reagents: Time: 
70% ethanol ...iminutss 
80% ethanol 3 minutes 
90% ethanol 3 minutes 
100% ethanol 3 minutes 
100% ethanol 3 minutes 
100% ethanol 3 minutes 
Xylene 5 minutes 
Xylene 5 minutes 
Xylene 5 minutes 
Mount the stained slides 
Table 2-2C Summary of fixing procedures 
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2.4 Biochemical assay of pancreatic oxidative status 
Oxidative stress is implicated to be an important factor in the pathogenesis of acute 
pancreatitis. Depletion of GSH, lipid peroxidation and protein oxidation are the most 
common indicators for the assessment of oxidative stress development. Therefore, the 
levels of GSH, MDA and protein carbonyls in pancreatic tissue were measured in the 
present study. Moreover, the membrane-associated NADPH oxidase is believed to be 
one of the potential sources of reactive oxygen species in tissue injury. The changes of 
NAD(P)H oxidase activity in acute pancreatitis were also measured in the present study 
[Parks 1989; Dabrowski et al 1999]. 
2.4.1 Sample preparation 
Tissue samples were immediately removed, and frozen in - 7 0 � C of liquid nitrogen. 
Upon biochemical assays, tissue samples were thawed. 10 % (w/v) tissue homogenates 
were prepared in 100 mM ice-cold phosphorous buffer saline (PBS), pH 7.4, by 
homogenization with a Telfon-Glass homogenizer. 
2.4.2 Quantification of protein content 
Protein content in each pancreatic sample was quantified using a colorimetric method 
with a micro-plate reader. The 10 % (w/v) pancreatic homogenates were diluted 50 
folds with 100 mM PBS (pH 7.4) and the final dilution volume was made to 1 ml. 
Following the instructions provided by the Bio-Rad protein assay kit, 4 |LI1 of the diluted 
homogenate was mixed with 200 i^l of reagent dye diluent, which was made from a 5-
fold dilution of the original concentrated stock. Concentrations of bovine serum 
albumin (BSA) at 0.125, 0.25, 0.5 and 1.0 mg/ml were used for the construction of the 
protein-assay standard curve. The absorbance at 595 nm was taken with the micro-plate 
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reader. Protein concentration of each pancreatic sample was calibrated with the protein 
standard curve and expressed as mg per ml. Triplicate sets of measurement were 
performed in order to average out the reading or pipetting errors. 
2.4.3 Measurement of glutathione levels 
Depletion of the antioxidant glutathione in pancreatic tissue was measured 
spectrophotometrically in order to assess the cellular antioxidant capacity against the 
oxidative stress [Godin and Gamett 1992]. 400 [il of 10 % pancreatic homogenate was 
treated with 100 |al of 25 % (w/v) trichloroacetic acid (TCA) for precipitation of the 
cellular protein. The mixture was centrifuged at 13,000 rpm for 2 minutes in the 
Eppendorf micro-centrifuge. 200 jil of protein-free supernatant was added into 1000 |al 
of 0.1 M phosphorous buffer. Upon the addition of 50 of freshly prepared 3 mM 5'5-
dithiobis-2-nitrobenzoic acid (DTNB) (Sigma, USA) in 0.1 M phosphate buffer, the 
reaction started and was observed by the color change. The mixture was allowed 5 
minutes for reaction to complete. Optical density (OD) of each pancreatic sample was 
taken at 412 nm and corrected with its protein content. Known concentrations of DTNB 
were used in preparing the standard curve and pancreatic glutathione levels were 
expressed as nmol per mg protein. 
2.4.4 Assessment of protein oxidation 
Spectrophotometric quantification of protein-bound carbonyls was used to assess the 
degree of oxidative protein modification in tissue injury. The assessment was employed 
according to Reznick and Packer [1994]. Briefly, 500 jul of 10 % pancreatic 
homogenate was incubated with 500 )al of 2 % (w/v) streptomycin solution for 15 
minutes at room temperature in order to remove the nucleic acids in samples. The 
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mixture was centrifuged at 6,000 x g for 15 minutes. 400 |il of the nucleic acid-free 
supernatant was treated with 400 [d of 20 mM 2,4-dinitrophenylhydrazine (DNPH) 
(Fluka, Switzerland) in 2 M hydrochloric acid (HCl) for 1 hour at room temperature. 
Another 400 i^l of supernatant was treated with 2 M HCl only to serve as a blank, which 
was used to determine the protein recovery. The reaction was terminated by the adding 
of 400 111 of 20 o/o (w/v) TCA. The mixture was subjected to a centrifUgation at 6,000 x 
g for 2 minutes. The pellets were then rinsed with 800 i^l of ethanol — ethylacetate (1:1) 
for 3 times and once with 800 of 10 % (w/v) TCA. The protein pellets were 
dissolved in 750 of 6 M guanidine hydrochloride and the absorbance was read at 370 
nm with a micro-plate reader. The absorbance of the blank was subtracted from the 
obtained DNPH-treated reading in order for calculating the contents of protein carbonyl. 
2.4.5 Assessment of lipid peroxidation 
Lipid peroxidation in pancreatic tissue in terms of quantification of its degradation 
product, MDA, was measured following the method described by Kruse et al [2001]. 
Briefly, 250 [i\ of 10 % (w/v) pancreatic homogenate was incubated with 250 ILII of 1.22 
M phosphoric acid and 500 |LI1 of 0.5 % (w/v) thiobarbituric acid (TBA) (Sigma, USA) 
solution in a 9 5 � C water bath for 30 minutes. 400 |il of the TBA-treated sample was 
mixed with 720 of methanol and 80 of 1 M sodium hydroxide (NaOH) followed 
by a centrifugation at 13,000 rpm for 2 minutes in a micro-centrifuge. 20 |li1 supernatant 
was loaded into the jaBondapak C-18 column of the high-performance liquid 
chromatography (HPLC) autosampler (Hewelett Packard, USA) and eluted in a mobile 
phase, the MP solution, which was prepared with HPLC-grade methanol — 25 niM 
phosphate buffer (1:1) and was adjusted to pH 6.5. The separation of the loaded sample 
was monitored using the photodiode array detector and the eluted peak was observed at 
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532 nm. The integral area of the eluted peak calibrated with the protein concentration in 
pancreatic tissue was used to calculate the amount of the produced MDA content. A 
standard curve was prepared with known concentrations of MDA standards. The 
amount of pancreatic MDA was expressed as pmol per mg protein. 
2.4.6 Measurement of NADPH oxidase activity 
Reactive oxygen species generation including the superoxide anion production was 
measured in terms of NADPH oxidase activity with a chemiluminescent-based method 
as demonstrated by Zhang et al. [1999]. The 10 % (w/v) pancreatic homogenate was 
centrifuged at 1000 x g for 2 minutes at 4 to remove all cell debris and fat. 20 |LI1 of 
supernatant was diluted with 800 of PBS. 100 of 1 mM reduced form NADPH 
(Oriental Yeast Co. Ltd., Japan) was added as a substrate while 100 of 2.5 mM bis-TV-
methylacridinium nitrate (lucigenin) (Sigma, USA) was added as a chemiluminescent 
agent. Upon the addition of substrate and lucigenin, the release of photons started. The 
rate of light release was recorded and integrated with the TD-20/20 luminometer 
(Promega, USA) over a period of 5 minutes. The activity of NADPH oxidase was 
expressed as relative light unit (RLU) per second per mg protein. 
2.5 Studies of pancreatic digestive enzyme secretions from isolated acini 
2.5.1 Dissociation of acini from pancreatic tissue 
The dissociation of functional intact acini from pancreatic tissue using collagenase and 
hyaluronidase digestions with mild shearing forces has been demonstrated by 
Amsterdam and Jamieson [1972] and Williams et al [1977]. Pancreatic tissue was 
harvested, rinsed with PBS and trimmed from fat. The pancreas parenchyma was 
inflated with 5 ml dissociation medium using a 27 G needle in order to distend the 
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tissue. The dissociation medium (Table 2-3) was made with Kerbs-Henselit 
Bicarbonate (KHB)-Minimal Eagles Medium (MEM) (1:1), 60 U/ml purified 
collagenase (Sigma, USA), 1.8 mg/ml hyaluronidase (Sigma, USA), 0.05 U/ml a -
chymotrypsin (Sigma, USA), 0.2 mg/ml soybean trypsin inhibitor (Sigma, USA), 100 
U/ml penicillin and 0.1 mg/ml streptomycin (GIBCO, USA). The inflated tissue was 
dissected and transferred into a vial containing another 5 ml fresh dissociation medium. 
The vial was then placed in a 37 water bath with vigorous shaking for 20 minutes. 
Pancreatic acini were dispersed to a greater extent by gently pipetting up and down, and 
next filtered through a 150-|Lim mesh nylon screen (Sigma, USA). Acini were rinsed 
with 10 ml KHB-MEM (1:1) buffer containing 1 % (w/v) fraction V BSA and purified 
by centrifugation at 1000 rpm at 4 °C for 3 minutes. The acinar pellet was rinsed 3 
more times, each with 10 ml KHB containing 4 % (w/v) BSA. After rinsing, the pellet 
was re-suspended in 20 ml of incubation medium (Table 2-3). The incubation medium 
is similar to KHB but containing 10 mM -hydroxyethyl) piperazine-A/"-(2-
ethanesulfonic acid) (HEPES) and without bicarbonate addition. Its pH was adjusted to 
the value of 7.35. In the incubation medium, 0.3 mM phenylmethylsufonyl floride 
(PMSF) and 2 mM ethylenediamine-tetraacetic acid (EDTA) were added for the 
inhibition of pancreatic proteases. In the acute pancreatitis-induced model, edematous 
pancreas was harvested. The acute pancreatitis-induced pancreas was also handled with 
the same dissociation process except supplied with 4-fold enzymatic contents and 
extensive shearing forces. 
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Dissociation medium (10ml) 
Reagents: Amount required 
KHB ^ 
MEM 5 ml 
Collagenase 600 U 
Hyaluronidase 18 mg 
a-chymotrysin 0.5 U 
Soyabean trypsin inhibitor 2 mg 
Penicillin 1000 U 
Streptomycin 1 mg 
Incubation medium (10ml) 
Reagents: Amount required 
KHB (without HCO3) 20 ml 
HEPES 10 mM 
PMSF 0.3 mM 
EDTA 2 mM 
Table 2-3 Summary of the reagents in dissociation and incubation media 
2.5.2 Treatment with peptides and RAS inhibitors 
The suspension of acini was randomly divided into 4 main groups, CCK-treated, Ang 
Il-treated, Ang II +RAS inhibitor-treated and RAS inhibitor placebo groups. 3 ml of the 
acini suspension was transferred to each incubation vial for enzymatic secretion analysis. 
At the beginning of the 30-minute incubation period, 0.5 ml acinar suspension was 
transferred out from each vial and subjected to a centrifugation at 5000 rpm at 4 °C for 
2 minutes. In the CCK-treated and Ang Il-treated groups, 25 jul of the CCK or Ang II at 
different final concentrations (0.1 nM to 100 nM) was added to the incubation vials 
each containing 2.5 ml cell suspension. The suspension samples were incubated in a 37 
� C water bath with vigorous shaking for 30 minutes. At the end of the incubation, 
another 0.5 ml acinar suspension was taken from each vial, and was also subjected to 
centrifugation. The supernatant was saved for analysis of a-amylase and lipase 
secretion. 
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For the Ang II + RAS inhibitor-treated and RAS inhibitor placebo groups, the 3 
ml acini suspension in each vial was pre-incubated with 30 |LI1 of 1 |iM RAS inhibitors 
(losartan or PD 123319) for 15 minutes at room temperature. After the pre-incubation 
period, the acini suspension was handled with same procedures as the Ang Il-treated 
group received. However, the final concentration of Ang II was fixed at lOOnM in Ang 
II + RAS inhibitor-treated group while same volume of PBS was given to the inhibitor 
placebo group. 
For the acini from acute pancreatitis-induced models, treatments with CCK, 
Angll or RAS inhibitors were given exactly in same conditions as given to the non-
induced acini. 
2.5.3 Quantification of protein and DNA contents 
Prior to the centrifugation of the 0.5 ml acini suspension transferred out from the 
incubation vial, 4 i^l of the cell suspension was mixed with 200 |al of protein reagent 
dye in a micro-plate in order to determine the protein content in each suspension vial. 
Absorbance at 595 nm from the micro-plate reader was calibrated with the BSA 
standard curve in calculating the protein concentration. The protein quantification assay 
was done with triplicate sets of measurements. 
After the centrifugation of the acini suspension, pellets were saved for the acinar 
DNA extraction while the supematants were removed for enzymatic assays. 1 ml of 
DNAzol reagent (Invitrogen, USA) was added to each acinar pellet and the acini were 
lysed by gentle pipetting. To each sample, 500 |al of 100 % ethanol was added to 
precipitate the DNA. After centrifugation at 4000 x g for 2 minutes at 4 DNA 
pellets were obtained. The pellets were washed twice with 800 i^l of 75 % ethanol and 
were dissolved in 200 |LI1 of 8 mM sodium hydroxide. OD taken at 260 nm with the 
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micro-plate reader was used to calculate the DNA concentration. One A260 unit equals 
50 i^ g of double-stranded DNA per ml. 
2.5.4 Measurement of a-amylase and lipase secretions 
The secretion of a-amylase or lipase in the incubated samples was expressed as the rate 
of the enzymatic release during the incubation. The changes in absorbance throughout 
the 30-minute incubation were used to calculate the rate of release, i.e. reading taken at 
time 0 subtracted from the reading taken at time 30. The reading taken at time 0 was 
considered as the basal value of enzyme secretion. The assay procedures were 
mentioned in sections 2.2.2 and 2.2.3 for a-amylase and lipase respectively, except 
plasma samples were replaced with acinar cell suspension supernatant. 
2.5.5 RT-PCR analysis of RAS components in acinar cells 
Experimental procedures with appropriate optimization for semi-quantitative RT-PCR 
of pancreatic RAS components have been reported previously [Chan et al 2000]. The 
mRNA expression of RAS components including angiotensinogen, ATi receptor and 
AT2 receptor was assessed using RT-PCR standardized by co-amplification with the 
house-keeping gene P-actin, which served as the internal control. Briefly, total RNA 
was extracted from isolated pancreatic acinar cells, induced with or without AP, using 
Trizol reagent (invitrogen, USA) by following the manufacturer's instruction. 
Concentration and purity of RNA sample was determined from the OD measured with 
micro-plate reader at 260 nm. 5 |Lig of the total RNA was reverse-transcribed into 
CDNA according to the manufacturer's instruction (SuperScript II, GIBCO-BRL, USA) 
using oligo dT as a primer. In the reverse transcription process, the mixture was 
incubated at 42 °C for 50 minutes and the reaction was inactivated by heating at 72 °C 
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for 15 minutes. The cDNA was subjected to amplification by the polymerase-chain 
reaction with rat-specific primers for angiotensinogen, ATia receptor, AT2 receptor and 
p-actin. Each set of PGR mixture contained 0.8 |LI1 of cDNA template, 18 |LI1 of PGR 
buffer, 1 [x\ of primer mix (sense and anti-sense) and 0.2 id of Taq polymerase, and the 
reaction was carried out using a thermal cycler. The target sequences were amplified 
with 28 repeated denaturation cycles at 94 for 1 minute, annealing at 62 for 90 
seconds and elongating at 7 2 � C for 90 seconds. The PGR products were separated on 2 
0/0 agarose gels containing 0.5 \ig/m\ ethidium bromide and visualized by UV 
transillumination. The band sizes of the PGR products were determined using a size 
ladder as reference. The intensities of the bands were measured using the molecular 
imaging system (FluroChem, USA) and normalized to that of the P-actin internal 
control gene. 
2.6 Studies of RAS inhibitors on acute pancreatitis-induced systemic 
inflammation 
Measurement of myeloperoxidase (MPO) activity is a frequently used method for 
assessing the neutrophil infiltration in tissues, such as the lung and liver [Haqqani et al 
1999]. On the other hand, histopathology would be of assistance in the determination of 
the tissue injury. 
2.6.1 Systemic inflammation treatment 
SD rats were randomly assigned into control, acute pancreatitis, RAS inhibitor placebo 
(placebo) and acute pancreatitis + RAS inhibitor (AP+Inh) groups. Animals were 
injected with cerulein for induction of acute pancreatitis-associated systemic 
inflammation. A time course experiment was performed in addition to the designated 
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two-hour period. Cerulein, at 50 |ig/kg/hr, was given to animals in hourly intervals with 
maximal number of doses up to four and the animals were sacrificed at hour 4, 6, 8 and 
24. For the examination of the systemic inflammation induced by acute pancreatitis, the 
8-hour experimental period was selected. In the 8-hour experimental period, animals in 
acute pancreatitis and AP+Inh groups were given 4 i.p. cerulein injections in hourly 
intervals for the first 4 hours and were sacrificed 4 hours thereafter. In control and 
placebo groups, rats received 0.9 % NaCl saline instead of cerulein in same volume and 
at same time intervals. For prophylactic treatment, a single dose of RAS inhibitor 
losartan was intravenously given to placebo and AP+Inh groups 30 minutes prior to the 
first cerulein. For continuous treatment, the placebo and AP+Inh groups received 2 
hourly i.v. injections of losartan 30 minutes after the first injection of cerulein in 
addition to the prophylactic dose. Losartan was given at dosage of 200 |Lig/kg. The 
control and acute pancreatitis groups received isovolumetric i.v. injections of 0.9 % 
NaCl saline instead of losartan. 
2.6.2 Measurement of myeloperoxidase activity in lung and liver 
Neutrophil sequestration in tissues was assessed by measuring the myeloperoxidase 
(MPO) activity [Bhatia et al 2000]. Lung and liver tissues were removed, blotted dry 
and stored in -70 °C. After thawing, 10 % (w/v) tissue homogenate was prepared in 
ice-cold 20 mM phosphate buffer (pH 7.4) using a polytron homogenizer (Kinematica, 
Switzerland). The pellet was obtained after centrifugation at 10,000 x g for 10 minutes 
at 4 � C and was resuspended in 50 mM phosphate buffer (pH 6.0) containing 0.5 % 
hexadecyltrimethylammonium bromide (Fluka, Switzerland). The suspension was 
sonicated for 40 seconds with a sonicator probe, and centrifuged at 10,000 x g for 
another 5 minutes at 4 °C. 20 |LI1 of supernatant was incubated with the freshly-prepared 
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reaction mixture for 110 seconds at 3 7 � C . The reaction mixture was prepared with 
both 1.6 mM tetramethylbenzidine (TMB) (Farco Chemical Supply, USA) and 0.3 mM 
hydrogen peroxide dissolved in 80 mM phosphate buffer (pH 5.4). The 110-second 
reaction was terminated by the addition of 50 \i\ of 0.18 M sulphuric acid (H2SO4). 
Absorbance at 450mn was taken for calculating the tissue MPO activity (Afmai — Ainitiai). 
2.7 Statistical analysis 
For the measurement of hyperamylasmia, hyperlipasmia and parameters of oxidative 
stress, results were analyzed with one-way analysis of variance (ANOVA) and the 
Tukey's post hoc test in order to establish whether the differences among the control, 
acute pancreatitis group and inhibitor treatment groups were statistically significant 
(n=5). All values were expressed as mean 士 SEM. For the measurements of acinar 
secretions of pancreatic amylase and lipase, results were also analyzed with one-way 
ANOVA and Tukey's post hoc test for the multiple determinations from the Ang II-
treated and RAS inhibitor-treated groups (n=4). For RT-PCR analysis, all gel images 
were analyzed and quantified by an UV illuminator (FluroChem 8000 Advanced 
Fluorescence, Chemiluminescence and Visible Light Imaging, Alpha Innotech 
Corporation, CA, USA). The mRNA expression of RAS components was normalized 
to the image intensity of the internal control P-actin. Results were also expressed as the 
mean 士 SEM. Statistical comparisons and differences between mean values of control 
and acute pancreatitis groups were compared using unpaired Student's t-test. In all 
instances, p values lower than 0.05 were considered to be statistically significant. 
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Chapter 3 Results 
3.1 Time-course experiment of acute pancreatitis model 
The effects of cerulein-induced acute pancreatitis in terms of the changes in 
pancreatic tissue injury and oxidative status were examined with time-course 
experiments. The minimum time required for a distinguishable and detectable onset 
the cerulein-induced disease was determined to be 120 minutes in the present study. 
Two major parameters for the characterization of pancreatic tissue injury and 
oxidative stress, the plasma a-amylase activity and pancreatic GSH depletion 
respectively, were presented in the next sections. 
3.1.1 Effect of acute pancreatitis on tissue injury 
Hyperamylasemia in blood is one of the major markers for monitoring acute 
pancreatitis and its severity. After the induction of cerulein, the plasma level of a -
amylase started to rise at the earliest time-point minute 15 and elevated to the highest 
at the last time-point minute 240 as studied. However, the designated experiment 
period for acute pancreatitis model in the present study was set to 120 minutes 
because it was the shortest time period to statistically achieve the significant 
difference from the non-cemlein-treated control in terms of a-amylase activity after 
the onset of AP (Fig. 3-1 A). Pancreatic injury was also significantly detected in 
other parameters, such as plasma lipase activity and weight ratio of pancreas to body, 
at minute 120 (data not shown). 
3.1.2 Effect of acute pancreatitis on oxidative status 
With respect to the effect of cerulein on changes in oxidative status, the GSH 
depletion assay was performed for further confirmation that the time period chosen 
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was correct. The pancreatic GSH levels dropped dramatically as soon as at minute 
15. Again, minute 120 was the first time-point found to achieve the significant 
difference from the control in GSH depletion (Fig. 3-lB). Other markers for 
oxidative stress including protein oxidation and activation of NAD(P)H oxidase were 





S) 2 0 0 0 - I 
H _ _ _ _ 
Control 15 30 60 120 240 




志 I 15- _ 
" • l i l l i iB 
Control 15 30 60 120 240 
Time after the first cerulein injection 
(minutes) 
Fig. 3-1 (A) Time-dependent effect of cerulein on plasma a-amylase activity in rats. 
(B) Time-dependent effect of cerulein on pancreatic GSH depletion in rats. Acute 
pancreatitis was induced by i.p. injections of cerulein at 50 |ig/kg/hr. Values were 
expressed as mean 士 SEM, (n=5/group). * Significantly different from the control. 
49 
3.2 Evaluation of ramiprilat and saralasin on changes of acute pancreatitis-
induced pancreatic injury 
The ACE inhibitor, ramiprilat, is known to block the ACE from converting Ang I to 
Ang II; whereas the non-specific Ang II receptor antagonist, saralasin, is 
acknowledged to block Ang II from binding to its cognate receptors including both 
ATi and ATi subtypes. 
3.2.1 Changes in tissue injury and histopathology 
Release of digestive enzymes from the pancreas into the circulation is one of the 
most commonly used indictors for pancreatic injury as observed in cemlein-induced 
acute pancreatitis. In the present study, the plasma a-amylase activity in the 
cemlein-induced group was found to be 3 folds higher than the non-cemlein-treated 
control after the 2-hour induction of cerulein at 50 |ig/kg/hr. Prophylactic treatment 
with the non-specific Ang II receptor, saralasin, provided significant suppression in 
the aspect of plasma a-amylase activity in the animals with acute pancreatitis. The 
application of saralasin in the range of 5 to 40 )ag/kg was found effective. The result 
indicated an U-shaped dose response with respect to the protective effect starting 
from 5 |ag/kg and the less than maximal effect began at 40 ^ig/kg. As regards, the 
optimal dose of saralasin appeared to be 20 |ig/kg (Fig. 3-2). The same dosage-
response experiment was also applied to the ACE inhibitor ramiprilat. However, no 
protective action of ramiprilat against the a-amylase elevation was found within the 
range of 5 to 40 [ig/kg. In contrast, adverse effects appeared to occur at the doses 





� 2 0 0 0 n 
o 1500 ^ ^ A * 
liJ _ l . i l HJJJJJ 
0 5 10 20 40 
Dose of saralasin (log/kg) 
Fig. 3-2 Prophylactic dosage effect of saralasin on plasma a-amylase activity in rats. 
Acute pancreatitis was induced by i.p. injections of cemlein at doses of 50 |ag/kg/hr. 
Values were expressed as mean 士 SEM, (n=5/group). * Significantly different from 




^ 2000-, * 
H j u j j 
0 5 10 20 40 
Dosage of ramiprilat (lag/kg) 
Fig. 3-3 Prophylactic dosage effect of ramiprilat on plasma a-amylase activity in 
rats. Acute pancreatitis was induced by i.p. injections of cemlein at doses of 50 
l^g/kg/hr. Values were expressed as mean 士 SEM, (n=5/group). * Significantly 
different from the non-cemlein-treated control. A Significantly different from the cemlein-treated control. 
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Apart from hyperamylasemia, hyperlipasemia in blood is also a common 
consequence observed in cerulein-induced acute pancreatitis. After the induction of 
cerulein at 50 |ig/kg for 2 hours, the plasma lipase activity in acute pancreatitis group 
was found to be 4 folds higher than the non-cerulein-treated control in the current 
study. Prophylactic treatment with saralasin at 20 [ig/kg significantly reduced the 
plasma lipase activity in the acute pancreatitis-induced animal; however, the 
prophylactic treatment with ramiprilat did not inhibit the pancreatic lipase from 
releasing into the circulation in the course of acute pancreatitis. In addition, the 
hyperlipasemia was even more severe in animals pre-treated with ramiprilat at doses 
higher than 40 |ag/kg (Fig. 3-4). 
On the other hand, pancreatic edema formation is another primary marker for 
cerulein-induced acute pancreatitis, and is commonly evaluated by the gain of water 
content in pancreatic tissue. After the inductions of cerulein, the weight ratio of 
pancreas to body in the acute pancreatitis model was drastically increased more than 
3 folds when compared with the non-cemlein induced control in the current study. 
That was probably due to the formation of pancreatic interstitial edema in the course 
of acute pancreatitis. The prophylactic administration of saralasin at 40 |ag/kg was 
demonstrated to reduce the pancreatic edema formation as reflected by the decrease 
in weight ratio of pancreas to body. However, the treatment with ramiprilat did not 
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Fig. 3-4 Effects of saralasin and ramiprilat on plasma lipase activity in rats. Acute 
pancreatitis was induced by i.p. injections of cerulein at 50 ^ig/kg/hr. Animals were 
given a single i.v. injection of saralasin or ramiprilat at 20 ^ig/kg or 40 ^ig/kg 30 
minutes prior to the cerulein induction. Values were expressed as mean 士 SEM, 
(n=5/group). * Significantly different from the non-cerulein-treated saline control. 
A Significantly different from the cemlein-treated saline control. 
mm Non-cemlein-treated 
20-, ^ Cerulein-treated 
I : U J U J 
Saline Saralasin-20 Saralasin-40 Ramiprilat-20 Ramiprilat-40 
Fig. 3-5 Effects of saralasin and ramiprilat on pancreatic weight ratio. Acute 
pancreatitis was induced by i.p. injections of cerulein at 50 jig/kg/hr. Animals were 
given a single i.v. injection of saralasin of ramiprilat at 20 )ig/kg or 40 |ag/kg 30 
minutes prior to the cerulein induction. Values were expressed as mean 士 SEM, 
(n=5/group). * Significantly different from the non-cerulein-treated saline control. 
A Significantly different from the cemlein-treated control. 
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Under the histological examinations, the control pancreas was 
morphologically intact (Fig. 3-6A) whereas the acute pancreatitis-induced pancreas 
showed severe interstitial edema, cytoplasmic shrinkage and acinar necrosis (Fig, 3-
6B). No histological alteration was noted in pancreas treated with saralasin placebos 
(20 and 40 |ag/kg) when compared to the control pancreas (Fig. 3-6C, 3-6D). The 
focal expansion of the interlobular septae in pancreatitic pancreas was greatly 
improved by the prophylactic treatment with saralasin at both 20 lag/kg and 40 |ig/kg 
(Fig. 3-6E, 3-6F). In addition, the acute pancreatitis-induced cytoplasmic shrinkage 
and acinar necrosis were also reduced by the pre-treatment with saralasin. The 
positive histological influences of prophylactic treatment with saralasin were in close 
agreement with the experimental results obtained in previous analyses of tissue 
injury, i.e. reductions in release of pancreatic digestive enzymes and pancreatic water 
content. 
On the other hand, prophylactic treatments with ramiprilat at both 20 and 40 
|ig/kg did not provide any improvement in the aspects of acute pancreatitis-induced 
pancreatic edema formation and acinar cell damage. The pancreatitic pancreas pre-
treated with ramiprilat was observed with cytoplasmic swelling and acinar necrosis 
in a more severe form (Fig. 3-7E, 3-7F). Slight tissue edema formation was found in 
the pancreas pre-treated with ramiprilat placebos (Fig. 3-7C, 3-7D). 
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Fig. 3-6 Histological examinations (H&E staining) of rat pancreas on induction of 
acute pancreatitis with/without prophylactic treatment with saralasin. (A) Control 
pancreas, non-cemlein-treated; (B) acute pancreatitis-induced pancreas, cerulein-
treated; (C) prophylactic treatment with saralasin (placebo) at 20 jiig/kg; (D) 
prophylactic treatment with saralasin (placebo) at 40 |Lig/kg; (E) acute pancreatitis-
induced pancreas with saralasin treatment at 20 jag/kg; (F) acute pancreatitis-induced 






Fig. 3-7 Histological examinations (H&E staining) of rat pancreas on induction of 
acute pancreatitis with/without prophylactic treatment with ramiprilat. (A) Control 
pancreas, non-cerulein-treated; (B) acute pancreatitis-induced pancreas, cerulein-treated; (C) prophylactic reatment wi h r miprila  (placebo) t 20 |ag/kg; (D) rophylactic treatment with ramiprilat (placebo) at 40 |Lig/kg; (E) cut p n reatitisinduc d panc s w h ramiprilat reatment at 20 jiig/kg; (F acute pa creas with ramip ilat treatment at 40 jig/kg. (Ma nification, x 400) 
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3.2.2 Changes in oxidative status 
The Ang II receptor antagonist saralasin has been demonstrated in previous sections 
to possess protective properties against the cemlein-induced pancreatic injury. Its 
positive role in regulating oxidative stress would be lead to a great attention. 
Glutathione depletion, protein oxidation, lipid peroxidation and activation of 
NAD(P)H oxidase are the common markers for the detection of oxidative stress. In 
the current study, glutathione in acute pancreatitis-induced pancreatic tissue was 
depleted drastically by more than 50% when compared to the non-cerulein-treated 
control. The prophylactic treatment with saralasin at 10 )ag/kg and 20 |Lig/kg 
significantly suppressed the glutathione depletion in the cemlein-induced pancreas. 
The treatment at such doses restored the GSH levels by approximately 40% (Fig. 3-
8). 
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Fig. 3-8 Dosage effects of saralasin on GSH depletion in rat pancreas. Acute 
pancreatitis was induced by i.p. injections of cerulein at 50 )ig/kg/hr. Animals were 
given a single i.v. injection of saralasin at doses from 5 |ag/kg to 40 [ig/kg 30 minutes 
prior to the cerulein induction. Values were expressed as mean 士 SEM, (n=5/group). 
* Significantly different from the non-cerulein-treated control. A Significantly 
different from the cerulein-treated control. 
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Induction of cerulein could result in significant oxidative modification of 
proteins. An intensive increase in the content of DNPH-reactive protein carbonyls 
was obtained by approximately 50 % in the acute pancreatitis-induced pancreatic 
tissue when compared to the non-cerulein-treated control as a result of protein 
oxidation. Pre-treatment with saralasin from 5 |ag/kg to 40 idg/kg greatly reduced the 
level of the oxidatively modified proteins in the cemlein-treated pancreatic tissues. 
The protein carbonyl formation was obviously reduced even lower than the control 
level when saralasin was applied at the dose of 20 |ag/kg (Fig. 3-9). 
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Fig. 3-9 Dosage effects of saralasin on protein oxidation in rat pancreas. Acute 
pancreatitis was induced by i.p. injections of cerulein at 50 |ag/kg/hr. Animals were 
given a single i.v. injection of saralasin at doses from 5 |ag/kg to 40 |ag/kg 30 minutes 
prior to the cerulein induction. Values were expressed as mean 士 SEM, (n=5/group). 
* Significantly different from the non-cerulein-treated control. A Significantly 
different from the cemlein-treated control. 
58 
Apart from the oxidative modification of proteins, the cerulein induction 
could also cause lipid peroxidation as a consequence of acute pancreatitis. MDA, a 
thiobarbituric acid reactive substance, is the major product of lipid peroxidation. The 
pancreatic MDA level was markedly elevated by about 34 % in the cemlein-induced 
animals when compared to the non-cemlein-treated control. Prophylactic treatment 
with saralasin at doses from 5 to 20 |Lig/kg significantly attenuated the lipid 
peroxidation in acute pancreatitis-induced pancreatic tissue as reflected by the 
decrease in pancreatic level of MDA. However, the same protective effect was not 
observed at the higher dose of 40 [xg/kg (Fig. 3-10). That might be due to the 
toxicity of the high dose usage. 
The generation of superoxide anion radical catalysed by NAD(P)H oxidase is 
also one of the major consequences of oxidative stress. The NAD(P)H oxidase 
system was activated in the acute pancreaetitis-induced pancreas as its activity was 
found to be enhanced by virtue of using the cheminluminscent assay. Treatment of 
saralasin declined, to appreciable extent, the NADPH oxidase activation in cemlein-
induced pancreatic tissue; however, the inhibitory effect was not considered 
statistically significant (Fig. 3-11). In the four parameters mentioned, the saralasin 
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Fig. 3-10 Dosage effects of saralasin on lipid peroxidation in rat pancreas. Acute 
pancreatitis was induced by i.p. injections of cemlein at 50 |ig/kg/hr. Animals were 
given a single i.v. injection of saralasin at doses from 5 |ag/kg to 40 ^ig/kg 30 minutes 
prior to the cemlein induction. Values were expressed as mean 士 SEM, (n=5/group). 
* Significantly different from the non-cemlein-treated control. A Significantly 
different from the cemlein-treated control. 
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Fig. 3-11 Effects of saralasin on NADPH oxidase activity in rat pancreas. Acute 
pancreatitis was induced by i.p. injections of cemlein at 50 }ig/kg/hr. Animals were 
given a single i.v. injection of saralasin at doses from 5 |ag/kg to 40 |ag/kg 30 minutes 
prior to the cemlein induction. Values were expressed as mean 士 SEM, (n=5/group). 
* Significantly different from the non-cemlein-treated control. A Significantly 
different from the cemlein-treated control. 
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3.3 Evaluation of losartan and PD123319 on changes of acute pancreatitis-
induced pancreatic injury 
The administration of non-specific Ang II receptor antagonist saralasin was 
demonstrated to be protective against the acute pancreatitis-induced pancreatic injury 
and oxidative stress. It is therefore intriguing to define the differential effects of the 
specific Ang II receptor inhibitions of ATi and AT2 on the changes in acute 
pancreatitis-induced pancreatic injury, not only prophylactically but also 
therapeutically. 
3.3.1 Changes in tissue injury and histopathology 
As a major indicator of pancreatic injury, pancreatic edema was assessed in terms of 
the gain of water content in the pancreatic tissue in order for scoring the severity of 
acute pancreatitis. Prophylactic administration of the specific ATi receptor 
antagonist, losartan, reduced the formation of pancreatic edema in the cerulein-
induced pancreas at doses from 100 to 800 i^g/kg. The reduction was reflected by 
the decrease in the weight ratio of pancreas to body. Pre-treatment with losartan at 
400 and 800 ^ig/kg showed significant reductions in the pancreas to body weight 
ratio (Fig. 3-12A); however, pre-treatment with PD123319, the selective AT2 
receptor antagonist, at the same range of doses studied did not provide such effects 
(Fig. 3-12B). In the therapeutic treatment groups, losartan and PD123319 at 400 
j^g/kg exhibited similar results to the cerulein-induced animals as in the prophylactic 
treatment groups (Fig. 3-13). 
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Fig. 3-12 Dosage effects of prophylactic treatments with RAS inhibitors on the 
weight ratio of pancreas to body. (A) Prophylactic treatment with losartan; (B) 
prophylactic treatment with PD123319. Acute pancreatitis was induced by i.p. 
injections of cerulein at 50 jig/kg/hr. Animals were given a single i.v. injection of 
RAS inhibitor from 50 |Lig/kg to 800 [ig/kg 30 minutes prior to the cerulein induction. 
Values were expressed as mean 士 SEM, (n=5/group). * Significantly different from 
the non-cerulein-treated control. A Significantly different from the cerulein-treated 
control. 
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Fig. 3-13 Effects of therapeutic treatment with losartan and PD123319 on the 
weight ratio of pancreas to body. Acute pancreatitis was induced by i.p. injections of 
cerulein at 50 |ig/kg/hr. Animals were given a single i.v. injection of RAS inhibitor 
at 800 jig/kg 30 minutes after the onset of acute pancreatitis. Values were expressed 
as mean 士 SEM, (n=5/group). * Significantly different from the non-cemlein-treated 
control. A Significantly different from the cerulein-treated control. 
The assessments of plasma a-amylase and lipase activities are the widely 
established indicators for cemlein-induced pancreatic tissue injury. In the present 
study, the activities of a-amylase and lipase in plasma were dramatically elevated 
more than 3 folds and 4 folds respectively in the cerulein-treated rat model. Both the 
prophylactic and therapeutic administration of losartan at 200 |Lig/kg greatly 
suppressed the cemlein-induced pancreatic injury, as evidenced by the decreases in 
plasma levels of a-amylase (Fig. 3-14) and lipase (Fig. 3-15). On the other hand, 
neither the prophylactic nor the therapeutic treatment of PD 123319 at 200 lug/kg 
provided protective effect against the acute pancreatitis-induced injury, as indicated 
by the high levels of plasma a-amylase (Fig. 3-14) and lipase (Fig. 3-15). 
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Fig. 3-14 Differential effects of losartan and PD123319 on the plasmas a-amylase 
activity in rats. (A) Prophylactic treatment, animals were given a single i.v. injection 
of RAS inhibitor at 200 ^ig/kg 30 minutes prior to the cerulein induction; 
(B) therapeutic treatment, animals were given a single i.v. injection of RAS inhibitor 
at 200 )dg/kg 30 minutes after the onset of acute pancreatitis. Acute pancreatitis was 
induced by i.p. injections of cerulein at 50 |Lig/kg/hr. Values were expressed as mean 
士 SEM, (n=5/group). * Significantly different from the non-cerulein-treated control. 
A Significantly different from the cerulein-treated control. 
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Fig. 3-15 Differential effects of losartan and PD 123319 on the plasma lipase 
activity in rats. (A) Prophylactic treatment, animals were given a single i.v. injection 
of RAS inhibitor at 200 jag/kg 30 minutes prior to the cerulein induction; 
(B) therapeutic treatment, animals were given a single i.v. injection of RAS inhibitor 
at 200 |Lig/kg 30 minutes after the onset of acute pancreatitis. Acute pancreatitis was 
induced by i.p. injections of cerulein at 50 |ag/kg/hr. Values were expressed as mean 
士 SEM, with n=5. * Significantly different from the non-cerulein-treated control. 
A Significantly different from the cemlein-treated control. 
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In addition to the biochemical analyses, the effects of cerulein on histological 
alterations in pancreatic tissues were also examined in the present study. The control 
pancreas retained morphologically intact (Fig. 3-16A) whereas the cerulein-induced 
pancreatitic pancreas was detected with substantial damages including interstitial 
edema, cytoplasmic shrinkage and acinar cell necrosis (Fig. 3-16B). In those acute 
pancreatitis-induced pancreatic tissues, prophylactic (Fig. 3-16C) and therapeutic 
(Fig. 3-16D) treatments with losartan at 200 |Lig/kg ameliorated the severity of acute 
pancreatitis, as observed with less interstitial edema and acinar necrosis. In the 
losartan placebos, no notable change in intact integrity of pancreatic morphology was 
observed (data not shown). 
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Fig. 3-16 Histological examinations (H&E staining) of rat pancreas on induction of 
acute pancreatitis with losartan treatment. (A) Control pancreas, non-cemlein-treated; 
(B) Acute pancreatitis-induced pancreas, cerulein-treated; (C) cerulein-induced 
pancreatitic pancreas with prophylactic treatment with losartan; (D) pancreatic 
pancreas with therapeutic treatment with losartan. (Magnification x 400) 
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Under the histological examination, the cerulein-induced pancreatitic tissues 
with prophylactic (Fig. 3-17C) and therapeutic (Fig. 3-17D) treatments with 
PD123319 at 200 jag/kg were shown with no improvement in the severity of acute 
pancreatitis when compared to the cemlein-treated pancreas (Fig. 3-17B). The 
treatments with PD123319 did not reduce the formation of interstitial edema, acinar 
necrosis and cytoplasmic shrinkage in the course of acute pancreatitis. However, no 
significant histological alteration in the intact integrity of pancreatic morphology was 




Fig. 3-17 Histological examinations (H&E staining) of rat pancreas on induction of acute pancreatitis with PD123319 treatment. (A) Cont ol pancreas, non-cemlein-treat d; (B) acute p ncreatitis-induced pancreas, cemlein-treat d; (C) ruinduced pancreatitic pancreas with prophylactic treatm nt with PD123319; (D)c r lein-induced pancreatitic p ncreas with th rapeutic treatment with PD 123319.(Magnification x 400) 
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3.3.2 Changes in oxidative status 
Saralasin treatment has been demonstrated in previous sections to ameliorate 
cerulein-induced oxidative stress. Nevertheless, saralasin could not suppress the 
activation of NADPH oxidase to a significant level. The NADPH oxidase activity 
was enhanced by 40 % in the cerulein-treated pancreatic tissue when compared to the 
non-cemlein-treated control. Prophylactic treatment with the specific ATi receptor 
antagonist, losartan, at 200 ^ig/kg could reduce the enhanced activity by nearly 30 %; 
however, such a reduction was not observed in the prophylactic treatment with the 
selective A T � receptor antagonist, PD123319 (Fig. 3-18A). Similar suppressive 
results on NADPH oxidase activity were obtained in the therapeutic treatments with 
losartan and PD123319 (Fig. 3-18B). For a further confirmation of the protective 
actions of the specific ATi receptor antagonism, protein oxidation was assessed as 
another indicator for monitoring the changes in oxidative status. The pancreatic level 
of protein carbonyls was greatly elevated by 60 % in the cerulein-induced pancreatic 
tissue as proteins were oxidatively modified in the course of acute pancreatitis. 
Animal model pre-treated with losartan at 200 [ig/kg was found with a significant 
reduction in the formation of pancreatic protein carbonyls whereas no positive effect 
was provided by the pre-treatment of PD123319 (Fig. 3-19A). In the therapeutic 
treatment groups, losartan also exhibited similar effective reduction against the 
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Fig. 3-18 Differential effects of losartan and PD123319 on the NAD(P)H oxidase 
activity. The activity of NAD(P)H oxidase was expressed in relative light unit 
(RLU)/second/mg protein. (A) Prophylactic treatment; (B) therapeutic treatment. 
Values were expressed as mean 士 SEM, (n=5/group). * Significantly different from 
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Fig. 3-19 Differential effects of losartan and PD123319 on the oxidative 
modification of protein. The protein oxidation was expressed in terms of nmol 
protein carbonyl formed/mg protein. (A) Prophylactic treatment; (B) therapeutic 
treatment. Values were expressed as mean 士 SEM, (n=5/group). * Significantly 
different from the non-cerulein-treated control. A Significantly different from the 
cerulein-treated saline control. 
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3.4 Evaluation of acinar secretions of digestive enzymes 
Activities of a-amylase and lipase in the freshly isolated pancreatic acini were 
measured in order to investigate the roles of CCK-8 and Ang II in the regulation of 
acinar digestive enzyme secretions. In addition, the effects of RAS inhibition on 
acinar a-amylase secretion were also studied. 
3.4.1 Cholecystokinin octapeptide-induced acinar secretions 
In the present study, the secretory function of the freshly dispersed pancreatic acini 
was primarily examined in terms of their responsiveness to exogenous secretagogue 
CCK-8, which is the well-established hormone for stimulating exocrine secretion. 
The isolated pancreatic acini were found highly functional as implicated by the 
extensive secretions of a-amylase and lipase after a 30-minute incubation with CCK-
8. The CCK-stimulated release of a-amylase (Fig. 3-20) and lipase (Fig. 3-21) from 
pancreatic acini was exhibited in a concentration-dependent manner. The secreted 
enzyme activities started to level off at 10 nM of CCK-8. 
3.4.2 Angiotensin Il-induced acinar secretions 
Similar to the CCK-8 stimulation, exogenous Ang II was also demonstrated to 
stimulate acinar secretion of digestive enzymes in the current study. The acinar 
secretion of a-amylase evoked by Ang II was also found to be dose-dependent, i.e. 
from 0.1 to 100 nM (Fig. 3-22). However, the stimulatory potency of Ang II was not 
as high as CCK-8. For example, at the half-maximal dose of Ang II (10 nM), the 
acinar release of a-amylase was stimulated to only one forth of the effect of CCK-8. 
Apart from a-amylase, the release of lipase from pancreatic acini was also stimulated 
by all doses of Ang II studied. Nevertheless, the stimulation of lipase at low 
71 
concentrations of Ang II, 0.1 and 1 nM, were not statistically different from the basal 
secretion (Fig. 3-23). 
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Fig. 3-20 Dosage influence of CCK-8 on a-amylase secretion from isolated 
pancreatic acini. Values were expressed as mean 士 SEM, (n=4/group). 
* Significantly different from the non-CCK-8-treated control (basal). 
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Fig. 3-21 Dosage influence of CCK-8 on lipase secretion from isolated pancreatic 
acini. Values were expressed as mean 士 SEM, (n=4/group). * Significantly different 
from the non-CCK-8-treated control (basal). 
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Fig. 3-22 Dosage influence of Ang II on a-amylase secretion from isolated 
pancreatic acini. Values were expressed as mean 士 SEM, (n=4/group). 
* Significantly different from the non-Ang Il-treated control (basal). 
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Fig. 3-23 Dosage influence of Ang II on lipase secretion from isolated pancreatic 
acini. Values were expressed as mean 士 SEM, (n=4/group). * Significantly different 
from the non-CCK-8-treated control (basal). 
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3.4.3 Effects of losartan and PD123319 on a-amylase secretion 
Exogenous dose of Ang II at 100 nM was demonstrated to significantly stimulate the 
release of a-amylase from isolated pancreatic acini as mentioned in previous sections. 
In the current study, pre-incubation with the specific ATi receptor antagonist, 
losartan, (1 |LIM) diminished the Ang IL-evoked release of a-amylase from pancreatic 
acini almost back to the basal level. On the other hand, the pre-incubation with 
losartan alone at same dosage did not alter the basal release of a-amylase from 
isolated acinar cells (Fig. 3-24). 
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Fig. 3-24 Effect of losartan on Ang Il-stimulated a-amylase secretion from isolated 
pancreatic acini. Values were expressed as mean 士 SEM, (n=4/group). 
* Significantly different from the control (basal). A Significantly different from the 
Ang Il-treated control. 
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Dissimilar to the ATi receptor antagonism, the pre-incubation with the 
selective ATi receptor antagonist, PD 123319, (1 |aM) did not provide any inhibitory 
effect against the Ang Il-evoked secretion of a-amylase from the isolated pancreatic 
acinar cells. Nevertheless, the PD123319 placebo also did not exhibit any executive 
effect on the basal acinar secretion of a-amylase (Fig. 3-25). 
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Fig. 3-25 Effect of PD123319 on Ang Il-evoked a-amylase secretion from isolated 
pancreatic acini. Values were expressed as mean 士 SEM, (n=4/group). 
* Significantly different from the control (basal). 
3.5 Existence and regulation of acinar RAS by acute pancreatitis 
The evidence for the presence of RAS components in pancreatic acini and their 
regulations by acute pancreatitis were examined in this study. These were achieved 
by means of semi-quantitative RT-PCR. 
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3.5.1 Expression of angiotensinogen and its regulation by acute pancreatitis in 
acini 
RT-PCR analysis showed that mRNA of angiotensinogen, the mandatory component 
for a local RAS, was expressed in pancreatic acini. The amplified PGR product was 
312 base pairs (bp) in size as expected (Fig. 3-26A). There was a significant effect 
of acute pancreatitis on the expression of angiotensinogen mRNA. Acute 
pancreatitis elicited a significant increase in the mRNA expression for 
angiotensinogen when compared with its internal control, P-actin. The relative 
change of expression was about 1.5-fold, as demonstrated by the RT-PCR and image 
analyses (Fig. 3-26B). 
3.5.2 Expression of ATi receptor and its regulation by acute pancreatitis in 
acini 
The mRNA expression of ATi receptor was noted in the freshly isolated pancreatic 
acinar cells. The isoform ATia was the dominant type and its PGR product was 385 
bp in size as expected (Fig. 3-27A). The mRNA expression of ATia receptor was 
demonstrated with an up-regulation in acute pancreatitis when compared with its 
internal control. The RT-PCR and image analyses showed that the relative 
expression of mRNAs for ATi receptor to P-actin in acute pancreatitis was increased 
by approximately 1.8-fold (Fig. 3-27B). 
3.5.3 Expression of AT! receptor and its regulation by acute pancreatitis in 
acini 
The expression of AT! receptor mRNA was also detected in the freshly isolated 
pancreatic acini by RT-PCR. The expected size of the amplified PCR product of 
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ATi receptor was 511 bp (Fig. 3-28A). The relative expression of mRNA for AT2 
receptor was elevated by acute pancreatitis nearly 1.9-fold when compared with its 
control P-actin, as demonstrated by the image analysis (Fig. 3-28B). 
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Fig. 3-26 (A) RT-PCR analysis of mRNA expression for angiotensinogen in 
pancreatic acini. Lane M, DNA marker; lane 1, angiotensinogen expression 
in normal acinar cells; lane 2, angiotensinogen expression in acute 
pancreatitis-induced acini; lane 3, B-actin expression in control; lane 4, B-
actin expression in acute pancreatitis-induced acini. The arrows indicate the 
expected size of the amplified products — angiotensinogen (312bp) and B-
actin (240bp). (B) The relative expression was shown as angiotensinogen/B-
actin mRNA in normal and acute pancreatitis-induced pancreatic acini. Data 
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Fig. 3-27 (A) RT-PCR analysis of mRNA expression for ATia receptor in 
pancreatic acini. Lane M, DNA marker; lane 1, ATia expression in normal 
acinar cells; lane 2, ATia expression in acute pancreatitis-induced acinar 
cells; lane 3, B-actin expression in control; lane 4, B-actin expression in acute 
pancreatitis-induced acini. The arrows indicate the expected size of amplified 
products 一 ATia receptor (385bp) and B-actin (240bpX (B) The relative 
expression was shown as ATia/B-actin mRNA in normal and acute 
pancreatitis-induced pancreatic acini. Data were expressed as mean 土 SEM, 
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Fig. 3-28 (A) RT-PCR analysis of mRNA expression for AT! receptor in 
pancreatic acini. Lane M, DNA marker; lane 1, AT2 expression in normal 
acinar cells; lane 2, AT2 expression in acute pancreatitis-induced acinar cells; 
lane 3, B-actin expression in control; lane 4, B-actin expression in acute 
pancreatitis-induced acini. The arrows indicate the expected size of amplified 
products — AT2 receptor (51 Ibp) and B-actin (240bp). (B) The relative 
expression was shown as AT2/B-actin mRNA in normal and acute 
pancreatitis-induced pancreatic acini. Data were expressed as mean 土 SEM, 
(n=3/group). * Significant different from control. 
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3.5.4 Evaluation of RAS inhibitors in acute pancreatitis-induced acinar cells 
In the freshly isolated pancreati acini, the stimulatory role of Ang II has been shown 
in the previous sections. In this study, exogenous Ang II was also demonstrated to 
stimulate a-amylase secretion from the acute pancreatitis-induced pancreatic acini. 
The stimulated release of a-amylase from acute pancreatitis-induced acini was more 
than 2-fold higher than that from the normal acinar cells. The acinar release of a -
amylase was normalized with the protein content in the cells. Pre-incubation with 
the specific ATi receptor antagonist, losartan, significantly reduced the Ang Il-
evoked release of a-amylase from acinar cells. However, the AT! receptor 
antagonist, PD123319, did not exhibit any effect on the acinar release of a-amylase 
(Fig. 3-29). Both losartan and PD123319 were applied at dose of 1 ^M as previously 
tested in the normal acinar cells. In addition, the release of a-amylase was also 
normalized with the DNA content in acinar cells and was expressed as units per [ig 
DNA (Fig. 3-30). 
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Fig. 3-29 Effects of losartan and PD 123319 on a-amylase secretion from acute 
pancreatitis-induced pancreatic acini. Los: losartan; PD: PD123319; AP: acute 
pancreatitis. Values were expressed as mean 士 SEM, (n=4/group). * Significantly 
different from the control (basal). A Significantly different from the AP+Ang II 
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Fig. 3-30 Effects of losartan and PD123319 on a-amylase secretion from acute 
pancreatitis-induced pancreatic acini. The units of activity were expressed per jig 
DNA. Los: losartan; PD: PD123319; AP: acute pancreatitis. Values were expressed 
as mean 士 SEM, (n=4/group). * Significantly different from the control (basal). 
A Significantly different from the AP+Ang II group (non-RAS inhibitor-treated 
control). 
3.6 Preliminary data on acute pancreatitis-induced systemic inflammation 
3.6.1 Time-course experiment on lung injury 
The plasma hyperamylasemia is a common indicator for acute pancreatitis. A time-
course experiment up to 24 hours was performed to investigate the AP-associated 
injury in tissues other than the pancreas. Acute pancreatitis was induced by 4 i.p. 
injections of cerulein at 50 )ag/kg/hr; the plasma a-amylase activity was elevated to 
the highest level at hour 8 and almost returned to basal level at hour 24 (Fig. 3-31). 
On the other hand, the MPO activity, a measure of neutrophil infiltration, in 
pulmonary tissues was also increased time-dependently with the highest level found 
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Fig. 3-31 Time-dependent effect of cerulein on a-amylase activity in rats. Acute 
pancreatitis was induced by i.p. injections of cerulein at 50 jag/kg/hr. Values were 
expressed as mean 士 SEM, (n=5/group). * Significantly different from the control. 
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Fig. 3-32 Time-dependent effect of cerulein on lung MPO activity in rats. Acute 
pancreatitis was induced by i.p. injections of cerulein at 50 |ag/kg/hr. Values were 
expressed as mean 士 SEM, (n=5/group). * Significantly different from the control. 
82 
Besides the measurements of MPO activity, the acute pancreatitis-associated 
lung injury was further confirmed by the histological alterations in lung sections. 
The control lung retained morphologically intact aveoli (Fig. 3-33A). However, the 
acute pancreatitis-induced lung consisting of pulmonary inflammation, such as 
edema, alveolar thickening and infiltration of inflammatory cells, was observed as 
early as from hour 2 (Fig. 3-33B). The severity of pulmonary injury was time-
dependently increased up to hour 8 (Fig. 3-33C, D, E). The pulmonary injury was 
histologically improved greatly at hour 24 (Fig. 3-33F). 
3.6.2 Time-course experiment on liver injury 
In addition to the injury in lung, acute pancreatitis could cause injury in liver as well. 
A time-course experiment up to 24 hours was also performed to investigate the acute 
pancreatitis-associated liver injury. The liver MPO activity was also found to elevate 
significantly. However, the severity of acute pancreatitis-associated tissue injury in 
liver was not as serious as found in the lung. The liver was only influenced shortly 
after the onset of acute pancreatitis. The highest level of MPO activity in liver was 
found at hour 2. The activity was almost back to the normal level from hour 4 








Fig. 3-33 Histological examinations (H&E staining) of rat lung on induction of AP. 
(A) Control lung, non-cemlein-treated; (B) lung harvested after 2 hours of acute 
pancreatitis; (C) lung harvested after 4 hours of acute pancreatitis; (D) lung harvested 
after 6 hours of acute pancreatitis; (E) lung harvested after 8 hours of acute 
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Fig. 3-34 Time-dependent effect of cerulein on liver MPO activity in rats. Acute 
pancreatitis was induced by i.p. injections of cerulein at 50 j^g/kg/hr. Values were 
expressed as mean 士 SEM, (n=5/group). * Significantly different from the control. 
3.63 Evaluation of losartan on systemic inflammation 
As lung injury was significantly detected at hour 8 in the time-course experiment, the 
designated induction period for acute pancreatitis-associated injury in lung was set to 
8 hours by giving 4 i.p. injections of cerulein. Protective effect against acute 
pancreatitis-associated lung injury was found when 3 continuous hourly injections of 
the selective ATi receptor antagonist, losartan, at 200 |ag/kg were given to the acute 
pancreatitis-induced animals. The treatment with losartan significantly suppressed 
the plasma a-amylase activity by approximately 30 % when compared to the 
cemlein-treated control (Fig. 3-35). The decrease in pulmonary MPO activity by the 
administration of losartan was in agreement with the measurement of 
hyperamylasemia (Fig. 3-36). 
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Fig. 3-35 Effect of losartan on plasma a-amylase activity in rats. Acute pancreatitis 
was induced with 4 i.p. injections of cemlein at 50 )Lig/kg/hr. Values were expressed 
as mean 士 SEM, (n=5/group). * Significantly different from the non-cerulein-treated 
control. A Significantly different from the cemlein-treated saline control. 
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Fig. 3-36 Effect of losartan on pulmonary MPO activity in rats. Acute pancreatitis 
was induced with 4 i.p. injections of cemlein at 50 |Lig/kg/hr. Values were expressed 
as mean 士 SEM, (n=5/group). * Significantly different from the non-cerulein-treated 
control. A Significantly different from the cemlein-treated saline control. 
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Chapter 4 Discussion 
4.1 Actions of RAS inhibitors on the changes of tissue injury, oxidative 
status and histopathology in acute pancreatitis-induced pancreas 
Acute pancreatitis is an inflammatory disease that arises from the premature 
activation of acinar proteolytic zymogens in the pancreas. The inappropriate 
activation of digestive enzymes consequently causes acinar cell damage and finally 
leads to autodigestion of the gland. Since the pathogenesis of acute pancreatitis is 
complicated and undefined, the involvement of pancreatic digestive enzymes is just 
partly accountable to this disease. In fact, other important mechanisms such as the 
release of various inflammatory mediators [Osman and Jensen 1999], activation of 
phagocytes [Beger et al 2000] as well as the activation of the RAS and other 
vasoactive peptide systems could be involved. The RAS in the pancreas has been 
documented for its existence in a wide range of species including canine, rat, mouse 
and human [Leung and Chappell 2003]. In rats, the pancreatic RAS has been 
subjected to an up-regulation in an experimental model of cerulein-induced acute 
pancreatitis [Leung et al. 2000; Ip et al 2003]. Such an activation of the pancreatic 
RAS is believed to play an important role in the pathogenesis of acute pancreatitis. 
A body of evidence has been substantiated that Ang II may mediate inflammation by 
stimulating the synthesis of cytokines, chemokines and other inflammatory factors 
such as phospholipase A � and TGF-pl [Brady et al 1999; Saluja and Steer 1999]. 
The chain of events would be initiated subsequently, via the participation of the RAS, 
thereby resulting in the development of acute pancreatitis. To this end, the 
application of RAS inhibitors would be beneficial to the changes in the severity of 
pancreatic injury and the oxidative stress, as induced by acute pancreatitis. 
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4.1.1 Differential effects of ramiprilat and saralasin 
ACE inhibitor and Ang II receptor antagonist are commonly used as anti-
hypertensive drugs; besides, they are also applied to treat acute myocardiac 
infarction and diabetic nephropathy [Drexler et al 1987]. Most of their actions are 
dedicated to the inhibition of the RAS. In this regards, the ACE inhibitor, ramiprilat, 
exerts its effect at the mid-point of the RAS cascade by blocking the ACE from the 
conversion of Ang I to Ang II; whereas the Ang II receptor antagonist, saralasin, 
exhibits its effect at rather down-stream of the RAS pathway by blocking Ang II 
from binding to its cognate receptors. 
The pancreatic injury caused by acute pancreatitis is commonly characterized 
by the release of digestive enzymes from the pancreas into the circulation, the gain of 
pancreatic water content and the formation of tissue edema. In the present study, 
prophylactic treatment with ramiprilat did not show any inhibition on the acute 
pancreatitis-induced release of pancreatic a-amylase (Fig. 3-3) and lipase (Fig. 3-4) 
into the circulation. In addition, the treatment also did not reduce the gain of water 
content in pancreas (Fig. 3-5) and the formation of tissue edema (Fig. 3-7). When 
the ramiprilat was applied at a higher dose, the severity of pancreatic injury was even 
enhanced. On the contrary, prophylactic treatment with saralasin provided 
significant suppressions in plasma levels of a-amylase (Fig. 3-2) and lipase (Fig. 3-4) 
in animals with acute pancreatitis. The pancreatic water content (Fig. 3-5) and 
interstitial edema (Fig. 3-6) were also greatly reduced when saralasin was 
prophylactically administrated to the cerulein-induced animals. 
The differential effects of the two RAS inhibitors may be due to the 
involvement of bradykinin accumulation during the RAS blockades. ACE, is also 
known kininase II, cleaves its C-terminal dipeptide, Phe-Arg from bradykinin, thus 
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regulating the balance between the RAS and kallikrein-kinin system [Deddish et al. 
1996]. The application of ACE inhibitor not only inhibits the synthesis of Ang II, 
but also blocks the kininase II from the breakdown of bradykinin. Bradykinin is 
acknowledged to evoke vasodilation and increase vascular permeability [Voors et al. 
1995]. In addition, the ACE inhibition may also elevate the endogenous level of 
nitric oxide (NO) along with the level of bradykinin. It is known that NO is a potent 
inhibitor of leukocyte and hence could attenuate inflammatory processes. However, 
excess generation of NO under oxidative stress may lead to inflammatory responses 
through its reaction with superoxide anion to form peroxynitrite (ONOO ), which is a 
potent oxidant [Beckman et al 1990; Peng et al 1998]. In fact, ACE inhibitors have 
been reported to induce localized angioedema, pancreatic duct obstruction and even 
pancreatitis [Iliopoulou et al 2001; Muchnick and Mehta 1999]. On the other hand, 
Ang II could be generated from the non-ACE pathways such as chymase and 
cathepsin G systems [Dzau 1988], and thereby full suppression of the RAS cascade 
could not be achieved by the ACE inhibition alone. In this context, the harmful 
effects of ramiprilat in the acute pancreatitis-induced pancreas have been implicated 
by both biochemical and histological evaluations in the present study. 
Nevertheless, a recent study reported that chronic oral administration of ACE 
inhibitor alleviated chronic inflammation and fibrosis in pancreas, thus might be 
useful for treating chronic pancreatitis [Kuno et al 2003]. In that study, high doses 
of lisinopril (20 — 200 mg/L) were utilized to suppress the overexpression of the 
TGF-pi mRNA, which consequently prevented the activation of pancreatic stellate 
cells and the synthesis of extracellular matrix protein. In the current study, i.v. 
injections of ramiprilat at 40 |dg/kg enhanced the plasma levels of a-amylase and 
lipase, thus causing a more severe acute pancreatitis. Although both ramiprilat and 
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lisinopril are carboxy-containing ACE inhibitors, lisinopril contains a dicarboxylate 
in its chemical structure and possesses a higher potency relatively [Voors et al 1995]. 
The heterogeneity of different ACE inhibitors may lead to beneficial but also 
harmful outcomes in the treatments whereas the involvement of bradykinin and NO 
elevations would be more critical in the pathology [Hartman 1995]. The difference 
in pathogenesis of acute and chronic pancreatitis may also be accountable to the 
properties of ACE inhibitors in dissimilar manners. 
In support for the role of RAS in the pathogenesis of cemlein-induced acute 
pancreatitis, the prophylactic treatment with Ang II receptor antagonist, saralasin, 
was shown to be effective against the acute pancreatitis-induced oxidative stress. If 
the generation of reactive oxygen species overwhelms the capacity of the anti-
oxidant mechanisms in the cells, oxidative stress develops [Dabrowski et al. 1999]. 
The NAD(P)H oxidase system is a major source for the cellular formation of reactive 
oxygen species. Superoxide anion is the primary product of the system [Parks 1989; 
Babior 1999]. Increase in intracellular calcium and/or activation of protein kinase C 
could play a role in the regulation of the superoxide anion generation [Matsubara and 
Ziff 1986]. In this study, the activity of NAD(P)H oxidase was significantly 
suppressed by the prophylactic treatment with saralasin (20 |ag/kg) in acute 
pancreatitis-induced pancreas (Fig. 3-11). The result implicated that the 
development of oxidative stress via the activation of NAD(P)H oxidase system, 
together with the activation of RAS, was involved in the pathogenesis of acute 
pancreatitis. In other studies, Ang II has been suggested to stimulate the production 
of superoxide anion via the membrane-bound NAD(P)H oxidase system in 
phagocytes, and such stimulation could be inhibited by Ang II receptor antagonists 
[Dijkhorst-Oei et al 1999; Wolf 2000]. 
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GSH depletion, lipid and protein oxidative modifications are common 
markers for oxidative stress. GSH is generally regarded as the first line of defense 
against oxidative stress [Sweiry and Mann 1996; Dabrowski et al 1999]. The 
administration of glutathione precursor, GSH monoethyl ester, has been shown to 
limit the severity of cerulein-induced pancreatitis [Neuschwander-Tetri et al 1992; 
Demols et al 2000]. In the present study, the prophylactic treatment with saralasin 
at doses of 5 and 10 jag/kg demonstrated a significant GSH restoration (Fig. 3-8). 
Therefore, the RAS could have a role in regulation of GSH depletion and 
consequently the oxidative stress caused by acute pancreatitis. On the other hand, 
the increase in other markers for oxidative damage, such as protein oxidation and 
lipid peroxidation, would proceed to the disruption of cell integrity. In the course of 
acute pancreatitis, the degradation products of protein oxidation and lipid 
peroxidation, i.e. protein carbonyls and MDA, respectively, were found significantly 
elevated along with severe pancreatic tissue damage [Dabrowski et al. 1999]. The 
levels of protein carbonyls and MDA were significantly reduced by the prophylactic 
treatment with saralasin at doses from 5 to 20 ^ig/kg (Fig. 3-9, 3-10). Thus, the RAS 
could also have a role in the regulation of protein oxidation and lipid peroxidation 
caused by acute pancreatitis. However, the application of saralasin at dose of 40 
|Lig/kg appeared to potentiate lipid peroxidation (Fig. 3-10). That might probably due 
to the toxicity of the drug at high dose usage. Based on the experimental data 
obtained in the study, it is believed that the activation of pancreatic RAS is 
associated with not only the severity of pancreatic injury, but also the changes in 
oxidative status in acute pancreatitis. 
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4.1.2 Differential effects of losartan and PD123319 
Inhibition of the Ang II synthesis by the non-specific Ang II receptor antagonist, 
saralasin, has been demonstrated in previous section to provide protective effects 
against pancreatic injury and oxidative stress in acute pancreatitis; therefore, the 
synthesis of Ang II appears to contribute in the respective alterations. It is 
acknowledged that Ang II exerts its physiological functions by binding to its cognate 
receptors, designated ATi and AT2 [de Gasparo et al 2000]. In the present study, 
losartan, the specific ATi receptor antagonist, and PD123319, the specific AT2 
receptor antagonist, were applied to define the differential roles of both ATi and AT2 
receptors on the changes in tissue injury and oxidative status in cerulein-induced 
pancreas. 
With respect to the acute pancreatitis-induced pancreatic injury, both 
prophylactic and therapeutic treatments with losartan at 200 |ig/kg showed marked 
improvements. They were implicated by the significant decreases in the plasma 
levels of a-amylase and lipase along with the reduction in the pancreatic water 
content. However, prophylactic and therapeutic treatments with PD 123319 did not 
provide any effect on the severity of cerulein-induced pancreatic injury (Fig. 3-12, 3-
14, 3-15). The differential effects of the ATi and AT2 receptor antagonists would 
probably be due to their diverging or contrasting roles for Ang II [Sohn et al 2000]. 
The ATi receptor has been suggested to oppose some ATi receptor mediated-effects 
on cell growth, water and electrolyte balance [Hein et al. 1995; Munzenmaier and 
Greene 1996]. The results in the current study showed that the ATi receptor could 
contribute to the alterations of tissue injury and histology of the pancreas. In other 
words, losartan would be the suitable RAS inhibitor in the aspect of ameliorating the 
severity of pancreatic injury induced by acute pancreatitis 
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With reference to the protective effects of saralasin against oxidative stress, 
the specific Ang II receptor blockers are inferred to provide same positive influences. 
The differential actions of losartan and PD123319 on changes of oxidative status in 
cerulein-induced pancreas were confined in terms of their suppressive abilities in 
protein oxidation and NAD(P)H oxidase activation in the present study. In fact, Ang 
II has been suggested to stimulate intracellular formation of reactive oxygen species 
generation, such as superoxide anion, hence leading to oxidative stress [Wolf 2000]. 
The superoxide anion generation induced by Ang II was found mainly via the 
mediation of NAD(P)H oxidase system [Di Wang et al. 1999]. In this study, the 
NAD(P)H oxidase activity was reduced significantly in rats either pre-treated or 
post-treated with losartan at 200 |dg/kg when compared to the enhanced NAD(P)H 
oxidase activity in the cemlein-treated control (Fig. 3-18). However, no positive 
change in NAD(P)H oxidase activity was observed in treatments with PD 123319 
(Fig. 3-18). Indeed, the activation of NAD(P)H oxidase was demonstrated in 
endothelial cells via the regulation of ATi receptor for Ang II [Zhang et al 1999; 
Rueckschloss et al 2002]. In addition, Ang II has been also demonstrated to cause 
generation of superoxide anion via the NAD(P)H oxidase system in vascular tissues 
[Griendling et al. 1994]. On account of the protective effects of ATi receptor 
blockade, the linkage between the pancreatic RAS and the generation of reactive 
oxygen species was further supported in the current study. 
In parallel to the activation of NAD(P)H oxidase system, the development of 
oxidative stress was also reflected by the increase of protein oxidation. The DNPH-
reactive protein carbonyls are relatively more stable than other oxidative markers 
such as protein sulfide and disulfides. The generation of protein carbonyls could be 
caused by a number of oxidative processes related to the action of reactive oxygen 
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species [Reinheckel et al 1999]. Other than protein oxidation, reactive oxygen 
species could also mediate activations of cellular macromolecules, inflammatory 
response and tissue injury. In the present study, the elevated pancreatic level of 
protein carbonyls was significantly reduced by both prophylactic and therapeutic 
treatments with losartan, but not by the treatments with PD123319 (Fig. 3-19). Thus, 
the RAS in pancreas was shown to participate in the regulation of protein oxidation, 
in turn of oxidative stress, in the course of acute pancreatitis. Similarly, damage to 
proteins was reduced by the blocking of ATi receptor, but not the ATi receptor, in 
chronic kidney disease [Agarwal 2003]. Again, losartan appeared to be an effective 
RAS inhibitor in attenuating the acute pancreatitis-induced NAD(P)H oxidase 
activation as well as the protein oxidation. On the contrary, PD 123319 was not 
demonstrated with any effect in these aspects. Taken together, the ATi receptor, but 
not AT2, is believed to be responsible for the majority of the physiological effects of 
Ang II in cerulein-induced oxidative stress. However, some recent studies have 
suggested that the AT2 receptor may play a counter-regulatory role against the 
actions of Ang II mediated by the ATi receptor [Horiuchi et al 1999; Siragy et al 
1999]. 
Taken together, it is therefore plausible to speculate that ATi and AT2 
receptors may have differential roles and mechanisms in the regulation of changes in 
the severity of tissue injury induced by pancreatitis observed in the present study. In 
this regard, blockade of the ATi receptor by losartan could inhibit NAD(P)H 
oxdiase-dependent superoxide formation induced by cerulein. Consequently, this 
reduced oxidative modification of cellular macromolecules, inflammatory response 
and cellular injury in the pancreas. 
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4.2 Potential functions of RAS in pancreatic acinar secretions 
The pancreatic exocrine secretions are regulated at multiple levels, generally by 
hormonal factors including CCK, secretin, gastrin and intracellular calcium, as well 
as the cholinergic and adrenergic neural inputs. Pancreatic acini are mainly 
responsible for the exocrine secretion of digestive enzymes. Apart from the classical 
regulatory controls, many other mediating factors such as cytokines, prostaglandin 
and vasoactive peptides are found to stimulate the acinar secretion [Chey and Chang 
2001]. As reported by many studies, CCK agonist has been demonstrated for its 
regulatory role in the pancreatic acini as evidenced by the highly stimulated a-
amylase output [Niederau et al 1994; Saluja et al. 1999]. The vasopeptide, Ang II, 
is thought to be a potential stimulus. Major components of RAS have been 
discovered in the AR42J acinar cell line [Chappell et al 1995]. The existence of the 
intrinsic RAS would be of importance in the regulation of acinar exocrine functions 
including the secretion of digestive enzymes. In the present study, the pancreatic 
acini were freshly isolated from rat pancreas by enzymatic digestions followed with 
mechanical shearing. The isolated rat pancreatic acini were testified with 
secretagogue CCK-8 to preliminary check whether the acinar cells were functional 
after a series of digestion and washing procedures [Palmieri et al. 1990]. In order to 
examine the role of RAS, the pancreatic acini were exposed to stimulating 
concentrations of Ang II. The responsiveness of acinar cells to exogenous Ang II 
was evaluated in terms of the stimulation in release of digestive enzymes. 
The acinar secretion was assessed with the releases of both a-amylase and 
lipase in this study. The double measurements were taken to balance out the 
variations in the degree of synthesis and secretion of pancreatic enzymes in 
experimental cell suspension samples [Kim and Kim 1996]. The enzymatic activities 
95 
were further normalized with acinar protein and DNA contents of individual sample. 
Nevertheless, the proteolytic digestive enzymes, such as trypsin and chymotrypsin 
[Hirschi et al 1994; Saluja et al 1999], were not assessed in the current study. It 
was because the incubation medium contained protease-inhibiting reagents, such as 
PMSF and EDTA, which might influence the activities of the proteolytic enzymes. 
The RAS in the exocrine pancreas is thought to play an important role in 
regulating the cellular responses, such as secretion, growth and tissue damage of the 
acinar cells. In this study, the role of RAS in rat pancreatic acini was evaluated by 
observing the secretory responsiveness of acinar cells to the exogenous Ang II and 
the specific Ang II receptor antagonists in terms of the stimulated digestive enzyme 
secretions. 
4.2.1 Potential role of ATi receptor 
The ATi receptor for Ang II has been evidenced for its presence throughout the 
pancreas [Serina 2001]. Its existence has been further investigated in specific cell 
types of the pancreas. The mRNA expression of ATi receptor has been reported in 
the AR42J acinar cells [Chappell et al 1995]. In the present study, the RT-PCR 
analysis demonstrated that the isolated rat pancreatic acini expressed the mRNA for 
ATI receptor as well (Fig. 3-27). Similar to the findings in other tissues, the ATia 
was identified in this study as the dominant isoform for ATi receptor in rat 
pancreatic acini [de Gasparo et al. 2000]. 
The results in current study showed that exogenous Ang II (0.1 nM to 100 
nM) could evoke acinar secretion of digestive enzymes, including a-amylase and 
lipase, in a concentration-dependent manner (Fig. 3-22, 3-23). This stimulatory 
effect of Ang II suggested a physiological role of RAS in the pancreatic acinar 
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functions, which was consistent with the study in the AR42J acinar cells [Cheung et 
al 1999]. The RAS inhibitors, such as losartan and PD123319, would be useful to 
further evaluate the potential roles of Ang II, which is the major effector of a RAS. 
In the AR42J acinar cells, Ang II has been reported to dose-dependently induce the 
calcium signaling as shown by the elevation of free cytosolic calcium under fura-2-
based microfluorimetry [Bamhart et al 1999]. The blockade of ATi receptor by 
losartan, the specific ATi receptor antagonist, resulted in a significant reduction in 
the Ang II-stimulated cytosolic calcium in the AR42J acinar cells [Barnhart et al. 
1999; Chappell et al 2001]. Similar inhibition of losartan to Ang Il-evoked 
intracellular calcium was also found in the human endocardial endothelial cells 
[Jacques et al. 2003]. The ATi receptor, therefore, was responsible for the mediation 
of Ang Il-dependent intracellular calcium signaling. In this study, as the pancreatic 
acini were pre-incubated with losartan, the Ang Il-evoked a-amylase elevation was 
inhibited almost to the non-Ang Il-evoked basal level. Losartan alone was shown 
with no alteration in the basal a-amylase output (Fig. 3-24). This experimental result 
agreed with the finding as shown in the AR42J acinar cell line [Cheung et al 1999]. 
The effect of losartan supported the presence of ATi receptor on pancreatic acini as 
shown by the RT-PCR analysis; besides, it also implicated the role of ATi receptor in 
the Ang Il-stimulated release of digestive enzymes in pancreatic acinar cells. 
Consistent with previous results, ATi receptor seems to mediate most of the 
physiological functions of Ang II in cardiovascular, renal, hepatic and other target 
cells [de Gasparo et al. 2000]. Therefore, the ATi receptor may play a critical role in 
regulating the acinar functions including secretion of digestive enzymes and 
probably pancreatic injury in pancreatic acini. 
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4.2.2 Potential role of AT2 receptor 
Similar to the ATi receptor, AT2 receptor is also distributed throughout the pancreas 
[Serina 2001]. Apart from the detection of mRNA for ATi receptor, the isolated 
pancreatic acini also expressed the mRNA for AT2 receptor in the present study (Fig. 
3-28). The expression of ATi receptor is found predominant in majority of tissues 
including adrenal cortex, liver, vascular smooth muscle [Chiu et al. 1989; 
Whitebread et al. 1989]; however, the ATi receptor subtype has been reported to 
express in a significant amount in the AR42J acinar cell line [Chappell et al 2001]. 
Unlike the result of ATi receptor antagonism, the blockade of AT2 receptor by 
PD 123319 did not influence the Ang Il-evoked secretion of a-amylase from 
pancreatic acinar cells in the present study (Fig. 3-25). Although the AT2 receptor 
was found present in the isolated pancreatic acini, the AT2 receptor might not take 
part in regulating the acinar secretion of digestive enzymes. However, the AT2 
receptor could promote production of bradykinin and prostaglandin [Siragy and 
carey 1999], neuronal differentiation [Laflamme et al. 1996] and apoptosis [Yamada 
et al 1996] in cultured cells, and may counteract to ATi receptors. In addition, the 
AT2 receptor has been shown to negatively regulate the activation of tyrosine 
phosphatase activity and the phosphorylation of insulin receptor kinase in the AR42J 
acinar cells [Elbaz et al. 2000; Chappell et al. 2001]. Nevertheless, the role of AT2 
receptor for pancreatic acinar exocrine secretion in the pancreas needs to intensive 
investigations in the future. 
4.3 Regulation of RAS in acute pancreatitis-induced acini 
Gene expression of major RAS components in target tissues have been regulated by 
various conditions including hypertension and athersclerosis [Singh and Mehta 2003], 
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PET [Lam and Leung 2002], experimental acute pancreatitis [Leung et al. 2000], 
chronic hypoxia [Chan et al 2000], and bile-duct ligation [Paizis et al 2002]. These 
results suggested a role for the tissue RAS in the disease states. The regulation of 
RAS by acute pancreatitis in pancreatic acini was in particular interest of the present 
study. 
4.3.1 Regulation of RAS components in acinar cells 
According to the semi-quantitative RT-PCR analysis, there was a significant effect of 
acute pancreatitis on the expression in mRNA levels of major RAS components 
including angiotensinogen, ATi and ATi receptors in acute pancreatitis-induced 
pancreatic acini (Figs. 3-26, 3-27, 3-28). The increase in the relative mRNA 
expression of RAS components by acute pancreatitis in the isolated acinar cells 
found in the present study was consistent with the results obtained from whole 
pancreatic tissue [Leung et al. 2000]. When the acute pancreatitis-induced 
pancreatic acinar cells were exposed to exogenous Ang II, the a-amylase secretion 
was stimulated by 2-fold when compared to the stimulation in normal acinar cells 
(Fig. 3-29). Therefore, there may be a linkage between the changes in the Ang II-
stimulated secretory response and the up-regulation of RAS as evidenced by the 
molecular analyses. The up-regulation of angiotensinogen might contribute the most 
to the significant elevation of a-amylase secretion from the acute pancreatitis-
induced acinar cells. Angiotensinogen, which is the mandatory component for a 
local RAS, precedes the synthesis of Ang I as well as the consequent product Ang II. 
This series of conversions is believed not limiting to the circulating hormonal 
cascade [Lavoie and Sigmund 2003]. Recent studies suggested that the angiotensin 
products could be synthesized intracellularly within an intrinsic RAS. The local up-
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regulation of ACE activity in infracted tissue has been resulted in an increase of local 
Ang II generation, which in turn to stimulate fibrogenesis, in the course of 
myocardial infarction [Voors et al 1995]. An increase in pulmonary Ang II 
concentration was found in the course of bleomycin-induced lung injury; this result 
also suggested that the local generation of Ang II, which might play a possible role in 
the fibrotic response to acute lung injury [Marshall et al 2003]. In the present study, 
not only the mRNA of angiotensinogen was demonstrated with a significant increase 
in cerulein-induced acute pancreatitis, the Ang II cognate receptors were also 
subjected to up-regulations accordingly. Thus the increase in endogenous Ang II 
together with the up-regulated Ang II receptors might probably be responsible for the 
extra elevation of a-amylase secretion found in the AP-induced acinar cells. The 
resultant elevation of a-amylase output was in agreement with the up-regulated gene 
expressions of RAS components in the cerulein-induced pancreatic acini. 
4.3.2 Differential actions of losartan and PD123319 
In those AP-induced acinar cells, pre-incubation with the selective ATi receptor 
antagonist, losartan, was found to significantly inhibit the Ang Il-evoked elevation of 
a-amylase secretion (Fig. 3-29). The inhibitory effect of losartan in acute 
pancreatitis-induced acinar cells further supported the up-regulation of RAS, in 
particular the ATi receptor, by AP. However, when the same concentration of 
losartan (1 [iM) was applied to both acute pancreatitis-induced and normal pancreatic 
acini, the action of losartan was not effective enough to completely hold down the 
Ang Il-evoked elevation of a-amylase in acute pancreatitis-induced acini back to the 
basal level as it was observed in the normal acini (Fig. 3-24, 3-29). In fact, the basal 
a-amylase release has been reported to be significantly higher in the pancreatic acini 
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from rats with cerulein-induced acute pancreatitis [Bragado et al 1996]. Thus, there 
might come with the insufficiency of antagonist in blocking the extensive increase of 
AT] receptors present in the acute pancreatitis-induced acinar cells. The increase in 
endogenous Ang II was taken into account as well. Apart from the effect of the up-
regulated RAS, the elevation of basal a-amylase secretion in acute pancreatitis-
induced acini could be due to calcium toxicity as well as integrity damage of acinar 
cells [Bragado et al 1996]. In addition, the intracellular activation of pancreatic 
digestive enzymes, and hence the hypersecretion, might occur as an early event in the 
acute pancreatitis development [Gorelick et al. 1992; Saluja et al 1999]. Therefore, 
losartan was shown to be an appropriate antagonist for inhibiting the Ang Il-evoked 
acinar secretion of a-amylase in pancreatic acini; however, its application was not 
sufficient to restrain the resultant outcome from the complicated events of acute 
pancreatitis. 
On the other hand, the Ang II-stimulated a-amylase secretion was not altered 
by the pre-incubation with selective ATi receptor antagonist, PD 123319, in the acute 
pancreatitis-induced pancreatic acini (Fig. 3-29). Although the mRNA expression of 
AT2 receptor was demonstrated with an up-regulation in acute pancreatitis, the AT2 
receptor might not have a role in the regulatory functions of acinar secretion. This 
result was consistent with the previous experimental data. Therefore, PD 123319 was 
inefficient in attenuating the Ang Il-evoked acinar secretion, in both normal and 
acute pancreatitis-induced pancreatic acini. Nevertheless, the counter-acting 
relationship of the ATi and AT2 receptors was not clearly revealed in this study with 
respects to the regulation of acinar secretion of digestive enzymes. 
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4.4 Potential role of RAS in acute pancreatitis 
Interleukins, platelet activating factor and tumor necrosis factor-a, the well-
established inflammatory mediators, are activated in the circulation as a systemic 
feature of acute pancreatitis [Heath et al. 1993; Grewal et al 1994]. However, an 
elevation of plasma renin observed in acute pancreatitis patients implicated the 
involvement of RAS in the development of acute pancreatitis [Greenstein et al 1987]. 
Furthermore, the circulating RAS has been shown to mediate inflammation and has 
been associated with the generation reactive oxygen species and reactive nitrogen 
species [Fernandez-Alfonso and Gonzalez 1999]. Contemporary research studies 
suggested that an intrinsic RAS could be related to the circulating RAS directly or 
indirectly through the inflammatory mediators. A recent study has reported that 
ACE inhibitor could attenuate pancreatic inflammation and fibrosis in chronic 
pancreatitis [Kuno et al 2003]. In the present study, specific RAS inhibitors were 
administrated to assess the role of RAS in the pancreas in terms of pancreatic injury 
and oxidative stress induced by acute pancreatitis. 
4.4.1 Regulation of RAS components by acute pancreatitis 
Cemlein-induced acute pancreatitis could up-regulate the gene expression of major 
RAS components including angiotensinogen, ATi receptor, AT2 receptor and the 
ACE activity in pancreatic tissue [Leung et al. 2000; Ip et al 2003] as well as in 
acinar cells. The up-regulation of RAS components could play an important role in 
the regulation of inflammatory responses, microcirculation, oxidative stress and 
tissue injury. The generation of reactive oxygen species may establish the linkage 
between the activation of RAS and the development of oxidative stress and 
pancreatic injury in the course of acute pancreatitis. Cemlein-induced acute 
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pancreatitis has been also reported to up-regulate the gene expression of 
inflammatory cytokines (IL-lb, IL-6) in pancreatic acini [Yu et al. 2002]. Ang II has 
been regarded as a potent vasoconstrictor, and it has also been suggested to mediate 
the induction of inflammatory cytokines and the intracellular formation of reactive 
oxygen species [Wolf 2000]. Elevation in endogenous angiotensinogen has been 
observed in acute pancreatitis-induced pancreatic tissue as well as in the acinar cells. 
Taken together, the up-regulation of RAS components by acute pancreatitis could 
mediate the production of reactive oxygen species, e.g. superoxide anion via the 
NAD(P)H oxidase system, and the oxidative modifications of protein and lipid; 
hence leading to the development of oxidative stress and finally the pancreatic injury. 
4.4.2 Differential functions of ATi and AT2 receptors in acute pancreatitis 
The actions of RAS on the changes in severity of pancreatic injury and oxidative 
stress were examined by the specific ATi and AT2 receptor antagonisms in acute 
pancreatitis. According to the experimental results, losartan, the specific ATi 
receptor antagonist, provided protective effects against the AP-induced tissue injury 
and oxidative stress. In other words, ATi receptor was responsible for the mediation 
of the effects of the activated RAS in acute pancreatitis. The ATi receptor could 
regulate the secretion of digestive enzymes from pancreatic acini as shown in the 
present study and from AR42J acinar cell line [Cheung et al. 1999], as well as from 
the gland. In terms of tissue injury, ATi receptor could also regulate the formation of 
tissue edema. Losartan has been reported to reduce the formation of cerebral edema 
[AsieduGyekye and Antwi 2003] and the pancreatic edema in the present study. In 
terms of oxidative stress, losartan has been demonstrated to suppress the pancreatic 
NAD(P)H oxidase activity in the current study, and the same suppression was also 
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found in vascular endothelial cells [Zhang et al 1999] and isolated rat heart [Oudot 
et al 2003]. The membrane-bound NAD(P)H oxidase is primarily responsible for 
the induction of reactive oxygen species. In addition, the generation of reactive 
oxygen and nitrogen species has been shown to be mediated by RAS, probably via 
the ATi receptor [Wolf 2000; Mihm et al 2003]. The results from current study 
were in consistent with the previous findings as losartan provided protective effects 
against the AP-induced lipid peroxidation, protein oxidation and activation of 
NAD(P)H oxidase system. On the other hand, the AT� receptor was not 
demonstrated with a distinguished role in mediating the pancreatic injury in acute 
pancreatitis. In the present study, no alteration was found in pancreatic secretion of 
digestive enzyme and formation of tissue edema when PD 123319 was applied to 
acute pancreatitis-induced pancreas or acinar cells. However, the AT2 receptor has 
been suggested to regulate apoptosis [Weidekamm et al 2002]. Besides, the AT2 
receptor may not have a role in the regulation of oxidative stress in the pancreatitic 
pancreas. Indeed, no change in the activity of NAD(P)H oxidase, protein oxidation 
and lipid peroxidation was observed when PD 123319 was administrated to acute 
pancreatitis-induced pancreas in the present study. 
4.5 Conclusion 
The present study firstly addressed the effects of cerulein-induced acute pancreatitis 
on the changes of pancreatic injury, histopathology and oxidative status of pancreatic 
tissues. Secondly, the association between the activation of RAS in the pancreas and 
the acute pancreatitis-induced pancreatic injury/oxidative stress were further 
demonstrated. The potential role of the pancreatic RAS was revealed by the 
significant reductions in the severity of acute pancreatitis-induced pancreatic injury 
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and oxidative stress by RAS inhibitions. The up-regulation of RAS in the pancreas is 
believed to mediate a number of events in acute pancreatitis, such as the activation of 
NAD(P)H oxidase system, glutathione depletion, protein oxidation as well as lipid 
peroxidation. Through the application of specific Ang II receptor antagonists, ATi 
receptor was demonstrated to mediate the physiological functions of Ang II in acute 
pancreatitis. In the exocrine pancreas, the RAS in pancreatic acini was suggested to 
have a regulatory role in acinar secretion of digestive enzymes. Through the specific 
antagonism, ATi receptor was shown to mediate the Ang II-stimulated release of 
digestive enzyme. Besides, the RAS in the exocrine pancreas was also subjected to 
an up-regulation by acute pancreatitis as observed in pancreatic tissue; the acinar 
secretion of digestive enzyme was enhanced accordingly. Regulation of exocrine 
secretions could be mediated via the ATi receptor on pancreatic acini as 
demonstrated in the present study. Taken together, the RAS in the pancreas could 
have diverse actions in regulating functions of the gland, as well as its significance 
on changes in the severity of acute pancreatitis-induced tissue injury and oxidative 
stress. Therefore, future strategy for the inhibition of the pancreatic RAS may be of 
importance in the management of acute pancreatitis-induced pancreatic injury. 
4.6 Further studies 
Although acute pancreatitis could be a mild self-limiting disease, occasionally it 
could also lead to systemic complications, such as systemic inflammatory response 
syndrome and multi-organ dysfunction syndrome. Apart from the hypersecretion of 
pancreatic digestive enzymes, the release of various inflammatory mediators into the 
circulation is followed. The pathogenic mechanisms leading from localized 
pancreatic injury to system inflammation and multi-organ dysfunction are of 
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particular importance. However, they are not fully understood. Our preliminary 
results demonstrated the involvement of RAS in acute pancreatitis-associated 
systemic inflammation. Acute pancreatitis-induced pulmonary injury could be 
attenuated by RAS inhibition, in particular the ATi receptor blockade, as evidenced 
by the significant reduction in pulmonary MPO activity. Therefore, the pancreatic 
RAS could have important implications not only limited for the pancreatic diseases, 
but also for several acute pancreatitis-associated dysfunctions. To this end, further 
work on the association between the activation of pancreatic RAS and systemic 
inflammatory response syndrome and multiple organ dysfunction syndrome is being 
undertaken. 
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